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ABSTRACT 
In orthopaedics, as in many other medical fields, the use of implants has greatly 
improved the quality of life for an increasing number of patients. Nowadays, 
orthopaedic implants are used routinely worldwide for fixation of long bone fractures 
and non-union defects, for correction and stabilization of spinal fractures and 
deformities, for joint replacement, and for other orthopaedic and maxillofacial 
applications. Despite the rapid evolution of implant technologies and bone grafting 
techniques, there is still a great demand for novel and more sophisticated synthetic 
materials for bone applications. Among biomaterials used for bone-related applications, 
hydroxyapatite (HA) has received considerable attention due to its excellent bioactive 
and osteoconductive properties as it bonds to bone and enhances bone tissue formation. 
In particular, synthetic HA with crystals within the nanometer range (nanoHA) has 
superior functional properties due to its biomimetic chemistry and morphology when 
compared to the mineral phase of bone. However, adhesion of microorganisms on 
biomaterials with subsequent formation of antibiotic-resistant biofilms is a critical 
factor in implant-related infections and it is currently regarded as the most severe and 
devastating complication associated to the use of biomaterials. In this context, the main 
purpose of this work was the development of nanoHA based-anti-infective biomaterials 
to prevent or treat implant colonisation and, subsequent biofilm formation. To address 
this goal both inorganic and organic approaches were investigated. Initially a composite 
that combines the favourable biological characteristics of nanoHA and, simultaneously, 
possesses antimicrobial activity as expressed by ZnO was synthesized as dense discs 
and the primary objective was to determine whether the size of ZnO particles (from the 
micrometer scale down to the nanometer range), when incorporated into nanoHA, was 
playing an important role in inhibiting bacterial growth. The materials had robust in 
vitro antibacterial activity, with an inversely proportional relationship between particle 
size and antibacterial effect. Accordingly, the challenge of the following step was the 
continued research on nanoHA-ZnO composites but this time for the production of 
three-dimensional and interconnected porous granules. The experimental evidence 
supports the view that nanoHA-ZnO granules exhibited antibacterial activity not only in 
vitro but also in vivo, and the interconnected porous scaffolds support tissue recovery, 
with the presence of blood vessels and tissue regeneration in vivo. Regarding the 
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organic approaches, two bee-derived natural extracts, namely green and red propolis, 
were adsorbed on nanoHA substrates and their antibacterial effectiveness was observed 
through the reduction of bacterial growth and biofilm formation while being non-
cytotoxic to fibroblast cells. In a slightly different approach, the activity of three novel 
imidazole derivatives to prevent Candida spp biofilm formation as well as to eradicate 
pre-formed Candida spp biofilms on nanoHA substrate was studied. The antifungal 
agents displayed strong inhibitory effect on biofilm development as potent in vitro 
activity against sessile cells within biofilm. Overall, this work reached the aimed results 
and presents promising strategies that could improve the capacity to prevent or eradicate 
biofilms in medical devices. Nevertheless, comparing the results obtained with the 
various materials tested in this work, nanoHA-ZnO porous granules take the best 
position as candidates for translational research from benchside to bedside. 
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RESUMO 
A utilização de implantes médicos no campo da ortopedia permite melhorar 
substancialmente a qualidade de vida de um número cada vez maior de pacientes. Estes 
implantes são atualmente usados para fixação de fraturas ou defeitos ósseos, para 
correção e estabilização de fraturas na coluna vertebral, para substituição de articulações 
danificadas, entre outras aplicações ortopédicas e maxilo-faciais. Apesar do rápido 
desenvolvimento na área dos implantes e enxertos ósseos, continua a existir uma grande 
necessidade de novos e mais sofisticados biomateriais sintéticos. De todos os 
biomateriais utilizados em aplicações relacionadas com o osso, a hidroxiapatite (HA) 
atrai enorme atenção devido à sua excelente bioatividade e osseocondutividade, uma 
vez que se liga ao osso e conduz à formação de novo tecido ósseo. Em particular a HA 
nanométrica (nanoHA) apresenta propriedades funcionais superiores, dada a sua 
semelhança química e morfológica com a fase inorgânica do osso. Contudo, a adesão de 
microrganismos aos biomateriais com a subsequente formação de biofilmes, altamente 
refratários aos antibióticos, é um aspeto crucial nas infeções relacionadas com implantes 
médicos, e uma das complicações mais severas e devastadoras associadas ao uso clínico 
dos biomateriais. Neste contexto, o objetivo deste trabalho centrou-se no 
desenvolvimento de biomateriais resistentes à infeção baseados em nanoHA, para 
prevenir ou tratar a colonização microbiana e subsequente formação de biofilme. Para 
atingir este objetivo foram avaliados compostos orgânicos e inorgânicos. Inicialmente 
foram sintetizados compósitos que combinaram as características favoráveis da nanoHA 
com a intrínseca atividade antimicrobiana do óxido de zinco (ZnO). Numa primeira 
etapa avaliou-se a influência do tamanho das partículas de ZnO na inibição do 
crescimento bacteriano. Os materiais mostraram forte atividade antibacteriana in vitro 
sendo esta inversamente proporcional ao tamanho da partícula de ZnO. Numa segunda 
etapa sintetizaram-se estruturas tridimensionais, nomeadamente grânulos de nanoHA-
ZnO. Os resultados obtidos permitiram inferir que tais materiais mantêm atividade 
antibacteriana não apenas in vitro, mas também in vivo. A estrutura porosa, altamente 
interconectada, dos grânulos permitiu o crescimento de tecido in vivo e 
neovascularização. Relativamente às abordagens orgânicas, dois extratos naturais, 
nomeadamente própolis verde e vermelha, foram adsorvidos aos materiais de nanoHA. 
Os materiais resultantes mostraram-se eficazes na redução do crescimento bacteriano 
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bem como na inibição da formação de biofilme, mantendo citocompatibilidade quando 
incubados com fibroblastos. Numa abordagem ligeiramente diferente, a atividade de três 
novos compostos derivados do imidazole foram testados quanto à sua capacidade de 
prevenir a formação de biofilme por Candida spp bem como à sua capacidade de 
eliminação de biofilmes pré-formados na superfície de materiais de nanoHA. Os 
compostos apresentaram forte atividade antifúngica tanto no desenvolvimento do 
biofilme quanto em células embebidas no biofilme. Em termos gerais este trabalho 
apresenta abordagens promissoras que podem melhorar a capacidade de prevenção ou 
tratamento de biofilmes associados ao uso de biomateriais. De todas as abordagens 
testadas, os grânulos de nanoHA-ZnO foram aqueles que apresentaram maior potencial 
para a translação desde o estudo de bancada até ao paciente visando uma mais direta 
aplicação clínica. 
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1. Bone tissue engineering 
Bone is a remarkable organ playing key roles in critical functions in human 
physiology. The importance of bone becomes even clearer in the case of diseases such 
as osteogenesis imperfecta, osteoarthritis, osteomyelitis, and osteoporosis where bone 
does not perform adequately. These diseases along with traumatic injury, orthopaedic 
surgeries (i.e., total joint arthroplasty, spine arthrodesis, implant fixation) and primary 
tumour resection lead to or induce bone defects or voids [1, 2]. The high incidence of 
these conditions is evidenced by the 2.2 million bone grafts used annually worldwide in 
order to repair bone defects in orthopaedics, neurosurgery and dentistry. Therefore, the 
clinical and economic impact of bone defects treatments is staggering [3]. 
In view of these clinical events the ways to heal the impaired bone tissue in 
timely manner can be regarded as one of the most important tasks that biomedical 
engineering can contribute to. Implant technology is developing rapidly however, there 
is a significant proportion of patients with bone defects or non-unions impossible to 
healing by direct fixation alone. Consequently, there is a great demand for novel bone 
replacement and bone regeneration systems beyond traditional surgical strategies. 
Historically, the ‘gold standard’ treatment is autogenous bone grafting. In this case, 
bone tissue is transplanted from one site to another in the same patient, ensuring the 
histocompatibility and non-immunogenicity. However, harvesting autografts is 
expensive, painful, constrained by anatomical limitations and associated with donor-site 
morbidity due to infection and hematoma [4-7]. Another reasonable option for patients 
and surgeons is the use of bone tissue from one individual to another called allograft. 
Allografts can be collected from either living donors or non-living donors and must be 
processed within a bone tissue biobank [8-11]. Allografts offer the advantage of 
allowing the surgeon to place a graft of the same anatomic location, and thus with very 
similar mechanical and biochemical properties, as the recipient site [12]. However, 
allografts carry risks of donor to recipient infection (rate of incidence of 5.4%), disease 
transmission, and host immune responses along with possible graft rejection [13, 14]. 
Although both these types of bone grafts have been widely used, there is a strong 
motivation on the development of novel and more sophisticated synthetic materials, 
tissue-engineered, to repair segmental defects caused by the removal of infected tissue 
or bone tumours or to improve the bone healing response and regeneration of bone 
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tissue around surgically implanted devices, such as artificial joints replacements or 
plates and screws used to keep bone alignment. 
The fundamental concept behind tissue engineering is to utilize the body’s 
natural biological response to tissue damage in conjunction with engineering principles. 
Thus, tissue engineering can be defined as an interdisciplinary field that applies the 
principles of engineering and life sciences to develop biological substitutes [15]. 
Several major technical advances have been achieved in the field of bone tissue 
engineering during the past decade, especially with the increased understanding of bone 
healing at the molecular and cellular level. As a result, biomedical engineers have been 
developing a wide variety of synthetic substitutes which serve as two- or three-
dimensional templates to restore, maintain or improve tissue function [7, 15]. The use of 
such synthetic biomaterials also allows overcoming the main drawbacks of autograft 
and allograft procedures, including the elimination of disease transmission risk, fewer 
surgical procedures, a reduced risk of infection or immunogenicity, and the abundant 
availability of synthetic materials. 
What separates a biomaterial from all others is its ability to exist in contact with 
tissues of the human body without eliciting an unacceptable degree of harm to that body 
[16]. In bone tissue engineering, the first challenge lies in the selection and optimization 
of the ‘best’ biomaterial for medical applications that mimics native bone tissue [1]. 
Such ideal biomaterial is a matrix that acts as a temporary substrate allowing cell 
growth and tissue development. The biomaterial should be able to mimic the structure 
and biological function of the native extracellular matrix (ECM) in terms of both 
chemical composition and physical structure, and not evoke any adverse or excessive 
inflammatory response [2]. To address these physiochemical biomimetic requirements 
specifically, a synthetic bone scaffold or graft must provide appropriate mechanical 
support to the affected area, contain a porous architecture to encourage mesenchymal 
stems cells (MSCs) migration and grow on its surface (osteoconduction), support and 
promote osteogenic differentiation of MSCs (osteoinduction) and enhance production of 
ECM by osteoblastic cells present within the graft material (osteogenesis) towards 
biomaterial-host tissue integration (osteointegration), without an intervening layer of 
fibrous tissue [17-19]. Other properties that must also be addressed comprise 
degradation in a controlled manner to facilitate load transfer to developing bone, 
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produce non-toxic degradation products, not incite an active chronic inflammatory 
response, be capable of sterilization without loss of bioactivity, easy to use, and cost-
effective. Additionally, they can also deliver bioactive molecules or drugs in a 
controlled manner to accelerate healing and prevent pathology [1]. 
To fulfil all these requirements, a clear concept of bone biology, physiology, and 
anatomy is, therefore, essential. 
 
1.1. Bone properties 
Bone is a highly vascular mineralized connective tissue which plays a wide 
variety of critical roles in human physiology. Bones not only provide the basic 
mechanical support to the body by generating and transferring forces that are involved 
in locomotion, but bones such as skull or ribs, also serve to physically protect vital 
internal organs including brain, heart, and lungs. Additionally, bone is the main mineral 
reservoir for the body by storing minerals within, mostly calcium and phosphate but 
also many other ions, and also stores growth factors, fatty acids, heavy metals, and other 
toxic elements. Absorption and release of salts is the mechanism by which bones buffer 
the blood and prevent excessive pH changes. Some bones are multiple progenitor cell 
(mesenchymal, hematopoietic) housing [1, 20]. 
From the biological perspective natural bone is a porous nanocomposite material 
made up of inorganic components, primarily hydroxyapatite (HA), a calcium phosphate 
material, and a large diversity of organic components, mostly collagen fibrils, but also 
an abundance of other non-collagenous proteins and a minor amounts of lipids and 
osteogenic factors [1, 21, 22]. The mechanical strength of the composite comes from the 
inorganic HA, which, combined with type I collagen fibres and the rest of ECM, is able 
to provide a supportive scaffold. The nanoscale HA crystals are responsible for 
imparting an appropriate compressive strength, whereby collagen fibres, able to 
dissipate energy effectively, provide superior elastic properties, thus improving the 
mechanical behaviour of HA itself. Thus, the two components of bone enable it to be 
strong yet allow some elastic deformation [1, 21, 23]. However, the exceptional strength 
and toughness of bone derive not only from the synergetic combination of its mineral 
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and organic components, but also from its hierarchical, superstructural organization 
(Figure 1) [24]. 
 
Figure 1.Bone is a complex, hierarchically structured biological material that comprises 
macro, micro and nano components. The microstructure of cortical bone consists of 
osteons with Haversian canals and lamellae, and at the nanoscale, the structural units are 
collagen fibers composed of bundles of mineralized collagen fibrils with hydroxyapatite 
crystals (adapted from [20]). 
Further to its mineral and protein components, bone is also populated by cells, 
macromolecules, and blood vessels. To maintain a healthy regenerative bone structure, 
three cell types are involved, as follows: osteocytes involved in signal transduction of 
mechanical stimuli; osteoblasts which are differentiated from MSCs and whose primary 
function is to synthesize and secrete organic matrix and lay down pre-mineralized bone 
matrix, i.e., osteoid; and osteoclasts which are multinucleated cell derived from fusion 
of mononuclear hematopoietic precursors and whose primary role is bone resorption 
through the secretion of acids and proteolytic enzymes, that degrade the mineralized 
tissue under the influence of chemical cues [25, 26]. Osteoblasts may have two fates. 
They can either become embedded in their own bone matrix as osteocytes or undergo 
apoptosis (programmed cell death) [25]. 
Through the cooperative action of osteoblasts and osteoclasts, bone ECM is 
constantly being remodeled in response to physiological requirements [27]. Bone 
remodeling is a critical process that takes place during the organism’s lifetime and it 
accounts for its growth during the development stages of the body, for maintaining 
skeletal integrity, healing, blood calcium regulation, and accommodation of changes in 
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bone stress profiles. It is a complex process that occurs in three distinct phases: 
resorption (osteoclasts are activated through paracrine pathways to digest bone), 
reversal (mononuclear cells appear on the surface), and formation (osteoblasts produce 
and secrete ECM). Bone remodeling is responsible for adjusting the architecture and 
hence mechanical properties of bone as a function of mechanical and chemical 
signalling [28, 29]. 
One very important regulator in bone physiology, especially bone remodelling, 
is mechanical stimulation and cellular transduction. Bone cells are profoundly 
influenced by the loads that they experience in vivo. During skeletal movement, forces 
are transmitted to cells via direct strain, hydrostatic pressure, flow-induced shear and 
electric fields. Although osteocytes are generally considered to be the primary sensing 
cell, in vitro studies have shown that osteoblasts, osteoclasts and osteoprogenitor cells 
also respond to mechanical stimulation [30, 31]. Additionally, chemical cues also play a 
significant role in basic cell functionality such as migration, adhesion, proliferation, 
differentiation and ECM production. In all tissues, the extracellular environment 
contains a wide variety of molecular signal which can be found in immobile, insoluble 
hydrated macromolecules (collagen, fibronectin, etc.), soluble mobilized 
macromolecules (e.g., growth factors, transcription factors, cytokines), and also from 
the transmembrane proteins of neighbouring cells [32]. Regarding bone matrix proteins, 
osteoblasts are responsible for the production of most of the organic components of the 
matrix, including collagenous and non-collagenous matrix components, which not only 
serve to structurally support cells but also to provide a variety of chemical cues that 
regulate functionality. Bone is around 30% organic, 90% of which is collagen type I. 
The remaining 10% are non-collagenous proteins and include proteoglycans, matrix 
proteins, growth factors, and cytokines. The most abundant protein in bone matrix is 
osteonectin, also known as SPARC (secreted protein, acidic and rich in cysteine), 
followed by osteocalcin (OC). Other extracellular glycoproteins as osteopontin (OPN) 
and thrombospondin (bone sialoproteins) are also present. OC and OPN are well-used 
biomarkers of bone formation. Bone matrix also contains proteoglycans (e.g., biglycan 
and decorin) that can influence cell behaviour [24, 25, 33-35]. Mobile biochemical cues 
directing cell behaviour can be produced by local osteoblasts or delivered via the blood 
stream. Transcriptional and growth factors such as platelet-derived growth factors 
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(PDGFs), bone morphogenetic proteins (BMPs), insulin-derived growth factors (IGFs), 
and transforming growth factor-β (TGF-) have indisputable roles in the facilitation of 
osteoblast proliferation, differentiation, and subsequent bone formation and regulation 
[25, 26]. In addition to growth and transcriptional factors, systemic and local hormones 
such as parathyroid hormone influence osteoblast proliferation and differentiation [36]. 
In the event of an injury, bone regeneration is a complex, well-orchestrated 
physiological process of bone formation. The bone tissue injury initiates a cascade of 
events involving a number of cell types (i.e., neutrophils, macrophages, fibroblasts and 
MSCs) and intracellular and extracellular molecular-signalling pathways, with a 
definable temporal and spatial sequence, in an effort to optimise skeletal repair and 
restore skeletal functionality. Unlike other tissues, a number of bony injuries (fractures) 
self-heals without the formation of scar tissue, and bone is regenerated with its pre-
existing properties largely restored, and with the newly formed bone being eventually 
indistinguishable from the adjacent uninjured bone [29, 37]. However, for a variety of 
reasons (such as bone defects size, infection, and many others), injured or diseased bone 
may not be capable of repairing itself. For such clinical scenarios, an appropriate 
biomaterial must be used to correct the bone defect. 
 
1.2. Bone biomimetics biomaterials 
Biomimetism and bioinspiration represent important tools for the design and the 
synthesis of innovative materials and devices. Biomimetism for bone applications can 
be conducted at different levels of physical and chemical properties of the synthetic 
materials and they should mimic all the characteristics of biological tissues, in order to 
optimize their interactions, and to mimic biogenic materials in their functionalities [22]. 
Up to now, a variety of synthetic materials have been investigated for bone 
applications including metals, ceramics, polymers, and composites of these. Obviously 
these materials differ widely in both chemical and mechanical characteristics; however, 
they all have properties that make them ideal for use in bone applications [3, 33, 38, 
39]. 
Metals and metallic alloys as titanium and its alloys, stainless steel and cobalt-
chromium among others, are known as being biocompatible, strong, easy to give shape 
and relatively inexpensive. They are frequently used, in dental and orthopaedic 
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applications, to replace and offer support for damaged and healing bone due to the high 
mechanical strength and fracture toughness. However, metals generally have a modulus 
higher than that of bone which may induce stress shielding and do not biodegrade, 
which requires additional surgery and may impede native tissue ingrowth. Additionally, 
there are concerns related to metal ion and/or particles release through corrosion or wear 
processes that cause inflammation and allergic reactions, affecting biocompatibility and 
tissue loss [40-42]. Considering the limited utility of generally non-degrading synthetic 
bone scaffolds or fixation devices, the only realistic options for bulk biomaterial 
selection are ceramics and polymers. Due to their biocompatibility, tunable 
degradability, processability, and general versatility, polymers, copolymers and 
polymer-ceramic composites are the principal materials investigated for the 
development of synthetic bone scaffolds [1]. The most commonly studied natural 
polymers for the purpose of bone tissue engineering are collagen/gelatin, chitosan, silk, 
alginate, hyaluronic acid and peptides [43-46]. The drawbacks of natural polymers 
include a higher risk of infection, fixed degradation rates, and immunogenicity [1]. As 
an alternative, there are the synthetic polymers as polyesters [3, 33]. 
Last but not the least, ceramics are clearly the most biocompatible functional 
materials. They are generally defined as ‘inorganic, non-metallic materials’ and three 
main families are well-known: calcium phosphates (CaP), glasses and glass ceramics. 
Commonly, bioceramics are classified as bioinert or bioactive. An inert material can be 
biocompatible, but elicit minimal biological response from the physiological 
environment; this is, for instance, the case of alumina and zirconia used in the 
production of femoral head implants. On the contrary, bioactive materials present a 
reactive surface which allows the formation of bone tissue on its surface [38, 47, 48]. 
Bioactive ceramics can be further categorized as resorbable or non-resorbable. Overall, 
ceramics are widely used as an implant material but present particular problems 
regarding their mechanical properties in terms of fracture toughness and fatigue 
resistance [49]. Among them, CaP is an obvious choice and has consistently shown 
excellent cellular and tissue responses in vitro and in vivo as an optimal material to aid 
bone repair, replacement and regeneration as they bond to bone and enhance bone tissue 
formation [17, 50, 51]. It has been widely used as bone substitutes in the form of 
powders, granules, dense and porous blocks, mouldable paste and various composites 
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[52]. There exists a family of CaP and the properties of each compound can be 
characterised according to the proportion of calcium to phosphorus ions in its structure. 
One of the most widely used synthetic CaP ceramics is HA due to its chemical 
similarities to the inorganic component of hard tissues which makes it widely used in 
both research and clinical fields [49, 53, 54]. 
 
1.2.1. Hydroxyapatite 
Synthetic HA is a mineral from the family of apatites with chemical formula: 
Ca10(PO4)6(OH)2 and a hexagonal crystalline structure. It has a theoretical composition 
of 39.68 wt% Ca, 18.45 wt% P; Ca/P wt ratio of 2.151 and Ca/P molar ratio of 1.667. It 
has higher thermodynamic stability in aqueous media than other CaP ceramics within a 
pH range of 4.2-8.0 [49, 53, 54]. As aforementioned, the close chemical similarity to the 
inorganic component of natural bone matrix has led to extensive research efforts to use 
synthetic HA for a variety of biomedical applications [22]. As a bioactive ceramic, 
synthetic HA exhibits strong affinity to host hard tissues and the chemical bonding with 
the host tissue offers a greater advantage compared to most other bone substitutes such 
as allografts or metallic implants [50]. 
Besides its inherent osteoconductive and osteoinductive capabilities, 
physicochemical properties of synthetic HA crystals can be tailored to optimize their 
specific biomedical applications. Moreover, in biological conditions, the crystal 
structure of HA can accommodate extensive substitution of ions, so that human bone is, 
which affect both its cationic and anionic sublattices, crystal morphology, crystallinity, 
solubility and thermal stability [20, 22, 55]. 
Nowadays, through nanotechnology, it is possible to synthesize inorganic 
crystals within the nanometric range that offer some specific improvements compared to 
micro-structured HA. The importance of synthetic nanosized particles relates to the 
natural HA crystals seen in biology. As previously mentioned, the in vivo HA crystals 
are nanoscopic. Accordingly, synthetic inorganic crystals with nanometric dimensions 
can improve the biological responses of HA as a result of high bioresorbility, actual 
surface area, and surface structural disorder which increase crystal bioreactivity [2, 22]. 
At present, it is well established that nanoscale architecture of the material itself affects 
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the amount, distribution, density, conformation and orientation of adsorbed proteins and 
thereafter, will influence osteogenic cells [56-59]. For instance, Webster et al [60] have 
shown the effect of nanoscale topography in promote increased selective vitronectin 
adsorption (a protein that mediates osteoblast adhesion) that further enhances osteoblast 
activities as differentiation and proliferation. In a more recent work, Ribeiro et al [61] 
found that nanohydroxyaptite (nanoHA) substrates had an important role in the 
adsorption behaviour of fibronectin as well as osteonectin, and clearly affected the 
MC3T3-E1 osteoblast morphology, distribution and metabolic activity. Overall, such 
physical feature may improve biomaterial osteoinduction and osteointegration [2]. 
Additionally nanoHA powders exhibit improved sinterability and enhanced 
densification (due to their greater surface area), which may improve fracture toughness, 
as well as other mechanical properties. Even so, its intrinsic hardness and lack of 
flexibility restrict its use mainly to non-load-bearing applications [2]. 
Common applications of synthetic nanoHA include bone augmentation, coating 
of metallic implants or acting as fillers in critical-sized defect in either orthopaedic or 
dental applications [21, 22, 62]. As artificial bone grafts, scaffolds of nanoHA closely 
simulating spongy bone morphology have been developed and have been used in 
clinical settings to increase bone regeneration in a variety of orthopaedic and 
maxillofacial procedures. The scaffold design must obey key requirements as very high 
porosity with full interconnectivity. Such porous architectures define the mechanical 
properties of the scaffold, as well as the initial void space that is available for 
regenerating cells to attach, migrate and proliferate in order to form new tissues 
(including new vascularisation) and the pathways for oxygen and nutrient supply and 
waste removal. The rate of scaffold degradation must be tuned so that it provides the 
necessary structural support until the newly grown bone has sufficient mechanical 
strength to replace this supporting activity. At the end, the scaffold should be able to 
modulate osteogenesis and promote bone ingrowth, leading to successful tissue 
regeneration [33, 63-69]. As a coating material for implants, nanoHA stimulates bone 
growth around the implant creating strong bone-HA-prosthesis bonds and therefore, 
promoting direct osteointegration with juxtaposed bone. The presence of HA coatings 
also prevents the formation of fibrous tissue that could occur due to micro-movements 
of an uncoated titanium implant and also aid to meet the aesthetic requirements of some 
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implants [70-72]. Clinical results for HA-coated implants reveal that they have much 
longer life times after implantation than uncoated devices and they have been found to 
be particularly beneficial for younger patients [49]. 
Additional applicability has been found for nanoHA particles including the 
design of controlled release systems. HA is known for its binding capability to a wide 
variety of molecules either pharmaceutical species (e.g., antibiotics, anti-inflammatory 
drugs, and anticancer and anti-metastatic drugs) or nucleic acids for gene therapy. 
NanoHA solubility in vivo and its efficient cellular uptake are contributing factors [1, 
20, 73-76]. A recent interesting method to use nanoHA has been to couple it with 
magnetic particles or to polarise it [21].  
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2. Implant-related infections 
Bone-related implants should function in an appropriate fashion both 
mechanically and biologically, however, the surfaces of commonly used orthopaedic 
biomaterials are susceptible to colonization by microorganisms [77, 78]. Such 
colonization not only does precede acute and chronic infections, but it may also 
adversely compromise the functionality and performance of the implant itself [79, 80]. 
Therefore, the occurrence of infection seriously impairs the healing and regenerative 
capacity of a tissue and remains a major limitation in the long-term utility of 
orthopaedic implants leading to implant removal and consequent increased morbidity 
and even mortality [81]. 
While international efforts to minimize the risk of these infections are underway 
[82], orthopaedic implant-related infections or bone-associated infections continue to 
occur in large numbers. Current estimates suggest that the occurrence of infection after 
internal fixation varies between 0.4% and up to 16.1% depending on the type of 
fracture. After arthroplasties, peri-prosthetic joint infections occur in 0.3-1.7%, in 0.5-
2% and in 2-9% of patients after total replacement of the hip, knee and ankle, 
respectively [83]. In addition to human pain and suffering, direct medical costs 
associated with such infections are extremely high and often result in the removal of the 
orthopaedic implants and the need for a follow-up operation [81]. Revision cases with 
tissue debridement carry an increased risk of infection [84]. The incidence rate is 
therefore higher, with an estimated rate of 3.2 to 5.6% for both hips and knees [85]. 
Even if it failures concern a minor proportion of patients, the huge numbers of 
individuals nowadays bearing permanent implants imply that, at the end, the overall 
impact on the entire population and on the costs for the national health systems are 
enormous [86, 87]. Longitudinal studies in industrialized countries have indicated a 
clear trend for further increase [88]. The overall infection burden is projected to raise by 
4% between 2005 and 2030 for both primary and revision hip and knee arthroplasties. 
Higher life expectancy, advances in medical technology and treatment of younger 
patients will lead to greater demand worldwide for medical implants and eventually an 
increase in implant-associated infections that poses a serious threat for modern medicine 
[89-91]. 
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The classification of implant-related infection considers either the type of 
pathogenesis or the onset of symptoms after implantation. Pathogenetically, inoculation 
occurs either exogenously or haematogenously [92]. Exogenous infections typically 
take place during surgery or immediately thereafter and most likely occur by inoculation 
with only a few microorganisms from the ambient atmosphere of the operating room, 
surgical equipment and clothing worn by medical professionals or resident bacteria on 
the patient's skin or mucous membranes. On the other hand, haematogenous infections 
are acquired via bloodstream by bacteria already in the body at any time after surgery 
[93, 94]. Even though, the risk has been reported to be highest within the first year after 
implantation and this might be related to the presence of a foreign body which impairs 
the local host defence [95-97]. The interstitial milieu surrounding prosthetic implants is 
known to represent a region of local immune depression and a locus minoris 
resistentiae, often referred to as immune-incompetent fibro-inflammatory zone [98]. 
This immune deficiency leads to a reduced ability to clear microorganisms from the 
vicinity of the biomaterial, and any contaminating microorganism are therefore more 
likely to cause a implant-related infection [99]. In fact, experimental models have well 
enlightened that the critical dose of contaminating microorganisms required to produce 
infection is much lower when a foreign material is present at the surgical site [80]. 
Often, implant-related infection is classified according to the time of 
manifestation after implantation. Considering the novel classification proposed by 
Zimmerli, early infection occurs within the first 3 weeks postoperatively and is typically 
caused by highly virulent microorganisms such as Staphylococcus aureus or 
Escherichia coli. Delayed infection manifests between 3 and 10 weeks postoperatively 
and, in most of these cases, microorganisms of low virulence such as coagulase-
negative staphylococci (CoNS) or Propionibacterium acnes are responsible. Finally, 
late infection occurs more than 10 weeks after implantation. Both early and delayed 
infections are usually exogenously acquired while late infections typically occur after a 
symptom-free postoperative period and are caused by haematogenous seeding or by 
recurrence of inadequately treated early infection [83]. 
Prophylactic administration of antibiotics has been done routinely to patients 
who receive an orthopaedic device in order to prevent perioperative infection [100]. For 
optimal efficacy of the prophylactic agent, antimicrobial inhibitory concentrations must 
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be achieved in tissue at the time of incision and last during the entire procedure. 
Additionally, the literature strongly suggests that prevention or eradication of such 
infections is better achieved by using combinations of antibiotics rather than single 
therapy [85, 95, 101]. Overall, prophylactic administration has been shown to reduce 
the relative risk of wound infection by 81% compared with no prophylaxis [102]. The 
conventional systemic administration of antibiotics has however some major drawbacks 
including systemic toxicity with associated renal and liver complications, poor 
penetration into ischemic and necrotic tissue typical of post-traumatic and post-
operative tissue, and the need for hospitalization [103]. Moreover, prolonged use of 
antibiotics at higher doses to reduce the prevalence of such infections may lead to drug 
resistance, and potentially compromise bone growth, immune system surveillance and 
implant osteointegration.  
Other important phenomenon in the pathogenesis of implant-related infection is 
the survival of bacteria in the tissue surrounding implants. Though macrophages and 
granulocytes are present around an implant, the microorganisms cannot be cleared, due 
to the frustrated phagocytosis caused by the implantation of a biomaterial [96, 97]. In 
living bone tissue excised from a patient with recurrent, long-term osteomyelitis, 
bacteria were observed inside osteoblasts and osteoclasts, even in high numbers within 
resident macrophages [104-106]. The persistence of intracellular pathogens around an 
implanted biomaterial is therefore a major concern, as these bacteria are not as 
susceptible to antibiotic treatment as those associated directly with the implant which 
may represent a focus for clinical relapse episodes [107]. 
Implant-related infections are not only a consequence of host factors (such as 
obesity, rheumatoid arthritis, diabetes mellitus and immune-compromised status) [108]. 
The infecting agents as well as the characteristics of the implanted device including 
size, shape, material, topography and intended use are important variables [78, 109] 
(Figure 2). Of these three, microbial factors are probably the most important in the 
pathogenesis of implant-associated infection, whereas implant features are the most 
amenable to modification with the objective of preventing infection. 
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Figure 2. Interaction between the microorganism, the biomaterial and the host in the 
pathogenesis of implant-associated infections (adapted from [95]). 
As mentioned earlier, the orthopaedic implants must, among other features, be 
made of non-cytotoxic materials and obtain mechanical stability with the adjacent bone 
and soft tissue. Concerning integration of orthopaedic implants, Gristina coined the 
phrase the ‘race for the surface’ suggesting that host cells and bacteria compete for 
positions on the implant’s surface [110]. A 6-h post implantation ‘decisive period’ has 
been identified during which prevention of bacterial adhesion is critical for the long-
term success of an implant. Over this period, an implant is particularly susceptible to 
surface colonization and at extended periods, certain species of adhered bacteria are 
capable of forming a biofilm at the implant-tissue interface which is considered the 
primary cause of implant-associated infection. Implantation will be therefore successful 
only if tissue integration occurs prior to considerable bacterial adhesion [110, 111]. 
Accordingly, orthopaedic devices are expected to stimulate host tissue 
integration and prevent microbial adhesion and colonization. However, the balance 
between these two requirements is often challenging. Biomaterial surfaces that facilitate 
host cell adhesion, spreading and growth are also favourable to microorganisms that 
share many of the same adhesive mechanisms as host cells. For instance, several 
bacteria have adhesins for fibronectin, which is a host protein that is frequently 
Microorganism 
Host Biomaterial 
Virulence 
Immune system 
Biocompatibility 
Adhesion 
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associated with bacterial attachment to surfaces, followed by fibrinogen/fibrin, collagen, 
laminin and vitronectin [112]. On the other hand, surfaces and coatings designed to 
prevent bacterial colonization and biofilm formation may not effectively integrate with 
host tissues. Thus, the challenge is to develop new infection-resistant surfaces without 
further impairing, the local host immune competence or the potential for tissue 
integration [113]. 
 
2.1. Biofilm formation 
Upon adhesion to a surface (inanimate material or tissue), replicating adherent 
unicellular individuals (bacteria or fungi) can arrange themselves into a complex tertiary 
structure displaying spatial and functional heterogeneity, encased in an ECM within 
which they are protected from a wide variety of antimicrobial factors [112]. 
This highly protective biofilm phenotype enables microorganisms colonizing an 
implant surface to evade antibiotics and host immune responses. Microorganisms 
growing as biofilms are significantly less susceptible to antibiotics therapy and host 
immune defences than are free-floating (planktonic) forms of the same microorganism 
[114, 115]. It has been found that killing bacteria in a biofilm sometimes requires 
approximately 1000 times the antibiotic dose necessary to achieve the same results in a 
suspension of cells [115-118]. Therefore, systemic antibiotics are able to eliminate 
planktonic organisms but are often ineffective in treating infections resulting from 
biofilm-embedded organisms. Thus, while the planktonic growth mode is important for 
the bacterial spread, biofilms are necessary to allow bacteria to persist and to resist 
adverse environmental conditions that may lead to persistence of infection, despite 
continued aggressive antibiotic treatment, for up to several years before awakening in 
more virulent modes [119]. 
Microbial adhesion to an implant surface is a dynamic process and, 
conceptually, can be divided into two essential phases: reversible and irreversible. The 
former is mechanically and biologically less stable than the latter, and it involves 
reversible cellular association with the surface over the first 1-2 hours post-implantation 
and it depends on the cell surface characteristics of the microorganism and on the nature 
of the biomaterial. This non-specific association is mediated through long (e.g., 
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gravitational, van der Waals, and electrostatic interactions) and short (e.g., hydrogen 
bonding, dipole-dipole, ionic, and hydrophobic interactions) range forces. The second 
and irreversible phase begins approximately 2-3 hours later and is characterized by 
stronger adhesion between the bacteria and the biomaterial (Figure 3). Specific chemical 
reactions between compounds on the cell and substrate surfaces result in irreversible 
molecular bridging [111, 120, 121]. 
 
Figure 3. Representation of microbial adhesion to a biomaterial substrate. In phase I, 
the adhesion of planktonic microorganisms involves reversible cellular association with 
the surface. During Phase II, bacteria undergo irreversible molecular bridging with the 
substrate through cell surface adhesin compounds. After approximately 1 day, biofilm 
maturation and growth of the three dimensional community occur, surrounded by a self-
produced ECM, that protects the sessile population from host defences and 
systemically-administered antibiotics (Adapted from [111]). 
Regarding to the entire process of biofilm formation in vivo, the body typically 
reacts to biomedical implants by rapidly coating them with a conditioning film 
consisting of host plasma and connective tissue proteins and glycoproteins, such as 
fibronectin, vitronectin, fibrinogen, albumin, laminin, immunoglobulins and some 
plasma/tissue lipids. The exact format of the conditioning film is dependent on implant 
surface chemistry (charge and hydrophobicity), topography, the anatomic site and 
exposure time. This conditioning film affects then all the post-operative downstream 
events. Many of those proteins subsequently serve as specific receptors for colonising 
microorganisms or incoming mammalian cells. Regardless of what material is employed 
(e.g., metal, ceramic, polymer), the surface chemistry is instantly altered by this 
macromolecule adsorption [122-125]. Biofilm formation continues with the transport of 
planktonic cells to the substratum, which is governed by a combination of transport 
mechanisms (i.e., diffusion, convection, sedimentation, and motility) [120]. Once at a 
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substratum surface, microbial cells adhere, as previously described, by non-specific and 
thereafter, specific receptors [120, 121, 126]. Multiple specific receptors on the cell 
surface, called adhesins, bind to host molecules and different microorganisms use 
different adhesins to colonize implant’s surface [79, 112]. After attachment, adherent 
(sessile) cells multiply and accumulate in multi-layered cell clusters which require 
intercellular adhesion, culminating in the formation of microcolonies. These organized 
structures are then surrounded by a self-produced ECM. Additionally, sessile cells up-
regulate the secretion of certain cell signal molecules that orchestrate community-wide 
phenotypic responses, through a process termed quorum-sensing (QS). Thus, bacteria 
can act as a population instead of as individuals [127-130]. Biofilms continue to mature 
by consuming soluble nutrients and recruiting other microbial species or mammalian 
cells (e.g., platelets) [131]. At this stage, biofilm morphology and topography becomes 
very distinct with mushroom-like macrocolonies [132]. The formation of cavities or 
hollow channels all over the biofilm is evident and they provide to the biofilm the 
transport system necessary to guide water, nutrients, planktonic bacteria and waste 
disposal throughout the community. Depending on other quorum cell signals, focal 
areas of the biofilm dissolve and the liberated microbial cells can be carried downstream 
giving rise to septicaemia or spread to another location where new biofilms can be 
formed [133]. 
In most biofilms, the microorganisms account for less than 10% of the dry mass, 
whereas the matrix can account for over 90% and is one of the most notable 
characteristic of adherent cells colonizing medical implants. Water is by far the largest 
component of the matrix, but the extracellular material is also composed by a variety of 
biomolecules known as extracellular polymeric substances (EPS), frequently referred to 
as glycocalyx or ‘slime’, which are originated from both the microorganisms and the 
surrounding environment. The EPS are mainly polysaccharides, proteins, nucleic acids 
and lipids; that forms the basis of the three-dimensional structure of the biofilm and 
immobilize the cells, keeping them in close proximity to each other [112, 131]. This 
physical proximity enables horizontal genetic transfer; in fact, the conjugation 
frequency appears to be higher in bacteria growing in the sessile mode than in the 
planktonic mode. As a result, microbial biofilms provide a suitable environment to 
facilitate the cross-breeding of resistance genes [134]. Additionally, the mutation rate of 
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biofilm-growing organisms is significantly increased compared with planktonically 
growing isogenic ones [135]. 
The biofilm resistance is multifactorial and may vary from one organism to 
another. This combination of factors makes biofilm eradication difficult [117]. Overall, 
three mechanisms have been proposed to explain the general resistance of biofilms to 
antimicrobial agents. The first is the barrier properties of the ECM. This mechanism 
might be more relevant for reactive, charged or large antimicrobial agents that are 
neutralized or bound by the EPS and are effectively ‘diluted’ to sub-lethal 
concentrations before they can reach all of the individual microbial cells within the 
biofilm. The hydrated matrix might also protect against antibody opsonisation and 
phagocytosis, UV light, dehydration, and might localize antibiotic-degrading enzymes 
[131, 136]. Even though, not all antimicrobial agents are equally affected; glycopeptides 
such as vancomycin and teicoplanin were significantly affected, whereas agents such as 
rifampin, clindamycin, and the macrolides were either unaffected or minimally affected 
[115, 137]. Although the presence of the matrix undoubtedly retards the diffusion of 
antimicrobial agents, the poor penetration does not fully account for the observed 
biofilm drug resistance. 
The second protective mechanism could involve the physiological state of 
biofilm-growing organisms. Biofilms are composed by a heterogeneous population of 
microbial cells that exhibit different metabolic properties creating multiple microniches 
[138]. Cells that are embedded deep within the biofilm might grow at a slower rate due 
to the lack of nutrients and oxygen in comparison with those located near the surface of 
the community. The formation of these starved, stationary phase dormant zones in 
biofilms seems to be a significant factor in the increase insensitivity to antimicrobial 
compounds, particularly against antibiotics such as β-lactams, which are effective 
against rapidly dividing Gram-positive bacteria. However, arguably all antibiotics 
require at least some degree of cellular activity to be effective, because the mechanism 
of action of most antibiotics involves disruption of a microbial process. Therefore, 
pockets of cells in a biofilm in stationary phase dormancy might represent a general 
mechanism of antibiotic resistance [112, 139, 140]. 
A third mechanism of protection could be the existence of sub-populations of 
resistant phenotypes in the biofilm that have been referred to as ‘persisters’. These 
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comprise a small fraction of the entire biofilm population and are in a particular 
physiological state with low levels of translation but a unique gene expression profile 
being inherently resistant to the actions of antimicrobial agents [141-143]. 
Accordingly, strategies to further reduce the rate of implant-related infections 
must target specific mechanisms involved in biofilm formation namely inhibition of 
microbial adhesion to the surface (first line of defence), interference with the signal 
molecules modulating biofilm development (second line of defence) or the possibility of 
disrupting biofilm matrix (third line of defence). 
 
2.2. Etiologic agents of implant-related infections 
The aetiology of implant-related infections is generally characterised by a broad 
variety of Gram-positive and Gram-negative bacteria as well as yeasts. Still, a high 
prevalence of staphylococcal species is listed (approximately 75%), first of all the two 
biofilm-forming species S. aureus and Staphylococcus epidermidis [87, 144, 145]. The 
former is a pathogen colonising the nostrils of a large proportion of the human 
population and the principal aetiological agent of nosocomial infections. Implant-related 
infections caused by S. aureus account approximately 35% of all the isolates, proceed 
rapidly and are generally more severe than S. epidermidis infections, followed by 
serious complications as severe sepsis, septic thrombosis and/or several deep-seated 
infections (endocarditis, osteomyelitis and other metastatic infections) [87, 146, 147]. 
On the other hand, S. epidermidis is a common saprophytic bacterium inhabitant of the 
human skin and mucous membranes, which has progressively emerged as a main 
opportunistic species with the growing use of implant materials and represents roughly 
30% of all the isolates [87, 148]. Apart from these two leading species, other 
staphylococci are emerging as new pathogens causative of implant-related infections. 
Among them other CoNS as Staphylococcus haemolyticus and Staphylococcus warneri 
contributing to an additional 10% of the infections. These bacteria take advantage of the 
weakening of the body defences at the implant surface-tissue interface since outside the 
setting of a medical device they rarely cause infections [80, 87, 94, 144, 149, 150]. Also 
Pseudomonas aeruginosa, Enterococcus faecalis, and bacteria of the 
Enterobacteriaceae family are commonly isolated from infected orthopaedic implants 
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[87, 144, 145]. Conversely, microorganisms of the Propionibacterium genus, in 
particular P. acnes, is commonly recovered from orthopaedic implants albeit it is a 
commensal species from normal skin flora and often considered non-pathogenic [151]. 
With regard to yeasts, the percentage of infections related to orthopaedic joint 
prostheses caused by Candida ssp is less than 1%, considering a rate of infections of 1 
to 3% this means 1-3 events per 10
4
 patients [152]. C. albicans represents the 
predominant and most virulent species among all isolates however, the importance of 
infections caused by Candida non-albicans, and other unusual yeasts (e.g., Malassezia 
spp, Rhodotorula spp, Hansenula anomala) has emerged over the last decade [153-
156]. Polymicrobial infections are observed in about 10-11%, and no organism is 
isolated in 10-30%, depending on the quality of the diagnostic procedure and preceding 
antimicrobial therapy [144, 157], meaning that, overall, these numbers may be 
underestimated and most probably are also increasing. An additional concern in recent 
years has been the increased number of reported infections due to antibiotic-resistant 
bacteria. In a large surveillance on surgical site infection after orthopaedic interventions, 
59% of the isolates were methicillin-resistant S. aureus (MRSA) [91, 144, 158].  
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3. Biomaterial modifications to mitigate infection 
Despite considerable recent progress in the development of nanobiotechnology 
and nanofabrication techniques, the quest to design and fabricate new antimicrobial 
surfaces as an integral component of advanced biomaterials remains a high research 
priority. The requirements that antimicrobial biomaterials need to cover are very broad, 
mostly depending on the type of biomaterial application [113, 159]. 
Antimicrobial surfaces can be categorized as passive or active depending on 
whether or not there are antibacterial agents delivered locally. Passive surfaces do not 
release bactericidal agents to the surrounding tissues; they only act on local bacteria that 
contact the surface. These surfaces may repel or resist the initial attachment of bacteria 
by either exhibiting an antibiofouling effect or by inactivating any cells coming into 
contact with the surface exhibiting a bactericidal effect. Antibiofouling surfaces impair 
cellular attachment due to the presence of an unfavourable surface chemistry and/or 
topography so that conditioning film do not form and/or bacteria-substrate interactions 
are not favourable; while bactericidal surfaces disrupt the cell upon contact, causing cell 
death [160-163]. On the other hand, active surfaces are designed to temporarily release 
high fluxes of pre-incorporated agents immediately following the implantation to down-
regulate infection. Those agents may have a direct antibacterial activity (e.g., 
antibiotics, silver, and nitric oxide), as well as an indirect antibacterial effects (e.g., 
antibodies) [103, 111]. Passive surfaces are preferred as long as their antibacterial 
ability is strong enough to prevent bacterial adhesion. However, the effectiveness of 
passive coatings is limited and varies greatly depending on the bacterial species and can 
also potentially be masked and inactivated when filmed by the host proteins present in 
protein-rich physiologic fluids. The efficacy of active coatings is directly related to the 
amount of the antimicrobial substance released that is influenced by the processing 
parameters, loading dose, applied technique, molecular size of the drug and the 
implants’ physicochemical properties [111, 164]. Antibacterial surfaces can be further 
categorized according to their functionality as mono- or multi-functional. The latter are 
expected to simultaneously target multiple biological tasks [163]. 
The following sections reviews some of the most successful approaches for the 
prevention of implant-associated infections, as well as promising perspectives for the 
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development of novel devices refractory to microbial adhesion, colonization and biofilm 
formation. 
 
3.1. Antibiofouling surfaces 
Modifications of the chemistry or the micro/nanotopography of the out-layer of 
an implant are key approaches in the development of innovative, adhesion-resistant 
materials or even microbial repellent surfaces since they play crucial roles in the 
kinetics of microbial adhesion. Alterations on such physicochemical properties are a 
relatively simple and economic way to counteract bacterial adhesion [113, 145, 165]. 
An efficient anti-adhesive surface should not only limit bacterial but also host proteins 
interaction to surfaces, therefore avoiding the formation of a conditioning film which 
may favour bacterial adhesion. In most cases, the implants are in contact with protein-
rich solutions and, as a result, rapidly formed conditioning film can be, in fact, the real 
interface with bacteria [166, 167]. 
Anti-adhesive surfaces in protein-low and protein-free media are usually inert 
material surfaces. They can be obtained acting on the biomaterial surface chemistry or 
on the surface morphology/topography. The same types of inert surfaces often exert 
their antifouling activity even under protein-rich fluids, as they scarcely bind ‘host 
adhesins’. In protein-rich fluids the dynamic of bacterial adhesion acquires a further 
degree of complexity. Under these circumstances, adequate surface chemistries may 
impair the adsorption of host adhesins, thus hindering the interactions with bacterial 
proteins. Therefore, conditioning protein-surfaces and/or protein-bacteria interactions 
are good strategies to inhibit bacterial adhesion to a specific biomaterial. The adsorption 
of proteins on a surface can be reduced either by altering the interaction potential (so 
that protein-surface interactions are suppressed) or by slowing down the rate of 
adsorption through high potential barriers for the interaction [145]. 
Regarding biomaterial surface hydrophobicity, it is generally accepted that 
hydrophobic bacterial cell surfaces adhere better to hydrophobic biomaterial surfaces 
due to a reduction in free surface energy [120, 126, 168]. Non-specific inhibition of 
adhesion is, therefore, obtained by coating the implant surface with hydrophilic 
materials. For instance, Patel et al [169] found that polyethylene oxide (PEO), a 
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hydrophilic polymer, significantly inhibited S. epidermidis biofilm formation over 48 
hours. In another study, surfaces of metals were coated with polyethylene glycol (PEG) 
and PEO, and the authors concluded that such modifications were able to hamper 
protein absorption and subsequent bacterial adhesion to biomaterial surfaces since these 
are highly hydrated polymer chains [170]. In a more complex approach, effective low 
adhesion surfaces may consist in hydrophilic, highly hydrated and non-charged surfaces 
as those obtained with long chain polymers to form a brush-like structure on the surface. 
The density of the chains provides a steric barrier that repels bacteria by minimizing 
covalent interactions [171-173]. In an exhaustive study, Hook et al [174] assessed 
hundreds of polymeric materials using a high throughput microarray assay and 
identified a group of structurally related materials that substantially reduced the 
attachment of P. aeruginosa, S. aureus and E. coli. Then, coating silicone with these 
‘hit’ materials showed to be effective at reducing S. aureus attachment in vivo in a 
mouse implant infection model. 
Following an opposed trend, recently low-adhesive, super-hydrophobic and self-
cleaning surfaces found in nature have been investigated for their potentially 
antibiofouling characteristics. Animals and plants have indeed developed fascinating 
strategies over millions of years to prevent efficiently the colonization of their surfaces 
by pathogens. For instance, the surfaces of insect wings, shark skin, and lotus leaves 
exhibit antibiofouling properties by preventing contaminating particles, algal spores, 
and bacterial cells from attaching to their surface [175-177]. Based on these evidences, 
super-hydrophobic microstructure arrays named as slippery liquid-infused porous 
surfaces (SLIPS) were produced on a silicon wafer and had proved to prevent bacterial 
attachment under flow conditions [178]. 
Besides chemistry, the morphology of a surface can be structured and directed to 
reduce adhesiveness to bacteria, even to achieve an enhanced bactericidal activity [179-
181]. Recent studies with different nano-structured surfaces have demonstrated that 
surface topography can determine a different bacterial behaviour not just in terms of 
adhesion, but also in terms of cell metabolism [182-184]. Techniques such as 
micropatterning of antifouling surfaces have shown that bacterial-repellent and tissue-
friendly surfaces may be achieved. For example, Wang et al [185] created surfaces with 
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submicrometer-sized, non-adhesive microgels patterned on an otherwise cell-adhesive 
surface. 
 
3.2. Surfaces with anti-infective agents 
Antimicrobial compounds can be incorporated in the bulk or in the coating of a 
biomaterial, based on their chemical compatibility, to inactivate any microbial cell 
around the implant. They can simply be mixed to the ingredients during the phase of 
production (e.g., in setting cements), a posteriori absorbed in permeable or porous 
biomaterials, covalently bound to functionalised coatings, incorporated in self-
assembling mono/multilayer organic coatings, among others. The release can 
consequently occur by different modalities: diffusion to the aqueous phase, 
erosion/degradation of resorbable loaded matrices or hydrolysis of covalent bonds. 
Systems with different kinetics of delivery of the active principle have been achieved 
depending on the stability of the molecular bonds or of the rate of 
biodegradation/bioerosion of the matrices entrapping the antimicrobial agent [145, 186]. 
Numerous substances are known to possess antimicrobial properties yet such 
effect is rarely highly specific and uniquely oriented towards prokaryotic cells. Often it 
is associated to a certain degree of cytotoxicity, immunoreactivity, and genotoxicity 
which can potentially affect host cell viability in peri-prosthetic tissues and, in the 
presence of specific tissue tropisms of the chemical species released, even cells residing 
at distant anatomic sites [145, 163]. 
 
3.2.1. Inorganic agents 
Silver has been described as one of the earliest materials to be intentionally used 
in biomedical applications for its oligodynamic antibacterial activity, i.e., exhibiting 
bactericidal/bacteriostatic activity at very low concentration, against a wide variety of 
Gram-positive and Gram-negative bacteria [187]. However, since its early identification 
as a convenient anti-infective biomaterial, the use of silver as bulk material in medical 
devices has progressively been ceasing over time. Following an opposite trend, the 
utilization of this element in thin nanocoatings, in doped solid or hydrogel materials, in 
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the formulation of bioactive alloys and glasses, and in form of micro- and nanoparticles 
has progressively been flourishing [188-192]. Also, some metal oxides (i.e., TiO2, ZnO, 
SiO2), have been explored due to their intrinsic antimicrobial properties on a wide 
spectrum of bacterial species [193-198]. Several studies had confirmed the improved 
antimicrobial effect of these metals as nanoparticles [188, 191, 194, 199, 200]. The 
nanoparticles can be either deposited directly on the surface of the implant or applied in 
a biomaterial matrix [201, 202]. For example, Alt et al [203] found that bone cement 
loaded with silver nanoparticles showed high effectiveness against multi-resistant 
bacteria in the absence of in vitro cytotoxicity. In a more recent study, a silver-coated 
megaprosthesis was able to reduce the infection rate in bone sarcoma patients from 
17.6% (pure titanium) to 5.9% (silver group). Whereas 38.5% of patients in the titanium 
group ultimately had to undergo amputation when peri-prosthetic infection developed, 
these mutilating surgical procedures were not necessary in the study group [204]. 
Regarding copper, for instance, Cu-sputtered polyester has shown to have a very high 
bactericidal efficiency against a number of MRSA strains [205]. Similarly, 
nanostructured ZnO and TiO2 were able to reduce S. epidermidis adhesion and increase 
osteoblast activity required to promote the efficacy of orthopaedic implants [206]. 
The antimicrobial activity of the majority of metals is closely linked to the ionic 
or nano form rather than to the bulk material. Dissolved ions are biochemically active 
agents that can interfere with critical enzymes of the respiratory chain, cell membrane 
permeability, hydroxyl radical formation, and subsequent DNA damage [197, 207]. 
Though metals show attractive characteristics as antimicrobial agents, further 
information is needed regarding both their stability in physiological fluids and their 
biological safety. Some studies have shown that such metals can adversely affect 
surrounding cells and lead to potentially harmful accumulation in distant locations, 
especially when in the form of nanoparticles [208, 209]. Additionally, there is still 
concern over the potential acquisition of resistance by bacteria to metallic compounds, 
especially with respect to silver. It is believed that silver resistance is considered 
widespread, although this not being confirmed by exhaustive tests and it overuse could 
potentiate the problem [210, 211]. 
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3.2.2. Organic agents 
Since its conceptualization by Buchholz and Engelbrecht in 1970, the use of 
antibiotic-loaded acrylic cement for the management of prosthetic joint infection has 
been common practice among many orthopaedic surgeons [212, 213]. Even now, 
antibiotic-loaded cements are frequently applied in orthopaedics, especially in 
association with the replacement of infected prostheses due to the high risk of relapse. 
Overall, antibiotic-loaded implant coatings present a straightforward approach for the 
prevention of implant-associated infections and have generally shown favourable results 
regarding their efficacy. The primary advantage of delivering antibiotics directly at the 
site of implantation is that high local doses can be administered without exceeding the 
systemic toxicity level of the drug. Therefore, enhanced efficacy can be achieved at the 
implant site. Localized administration also allows for the tailored selection of antibiotics 
toward specific pathogens associated with implant infections, circumventing potentially 
harmful side reactions in other parts of the body [111, 214]. 
The ideal antibiotic delivery system should release the drug at optimal 
bactericidal levels for an appropriate therapeutic time frame to prevent potential 
infection, followed by a sustained release at an effective level to inhibit the occurrence 
of latent infection [1, 103]. In the case of implant-related infections it is important to 
fight bacteria that were introduced during the implantation and also those introduced 
systemically afterwards. A sustained release (second phase) is therefore necessary. 
Nevertheless, it should be ensured that in the second phase, the antibiotic concentration 
is at an effective level. Studies have reported that sub-inhibitory concentrations of 
certain antibiotics can actually enhance biofilm formation and for sure they can act by 
selecting and promoting the emergence of new antibiotic resistant strains [215-217]. 
Any undesired effect of antibiotics on tissue integration of the implant should be 
minimized when designing the antibiotic delivery system. 
Several antibiotics have been widely used, as well as delivery systems. 
Specially, HA coating is widely applied and the use of a bioactive ceramic coating as 
antibiotic carriers offers the added value of providing the physicochemical environment 
and structural scaffold required for bone-implant integration [218]. In vitro release of 
antibiotics from HA-coated implants has been reported for a broad range of drugs. For 
instance, Alt et al [219] investigate the antimicrobial effect of two different gentamicin-
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HA coatings for cementless prostheses in a rabbit infection model. After 28 days, both 
gentamicin-coating types showed significant reduction of infection rates compared to 
standard HA coating. Afterwards, still in an in vivo model, that author assessed the 
effects of gentamicin-HA coatings on new bone formation, implant integration and 
biocompatibility. Both gentamicin coatings revealed good biocompatibility and bone 
integration, which was not statistically different when compared with pure HA [220]. In 
this context, several other studies have been conducted [221-226]. 
The antibiotic-loading can be performed by surface-adsorbed antibiotics through 
immersion in antibiotic solutions. Although simple, this approach leads to rapid 
antibiotic release, excluding it as a method for preventing implant fouling over long 
periods. Other strategies include the embedding of antimicrobial substances in 
nanoceramics or surfaces coated with covalently linked antibiotics [218]. Antoci et al 
[227] observed that covalently bonded vancomycin to titanium alloy (Ti) pins prevented 
S. aureus colonization. Moreover, these authors confirmed that the attachment remained 
stable under a number of conditions, including exposure to fluid environments, press-fit 
insertion into bone, and saturating levels of S. aureus. Besides Antoci work, several 
other authors have shown that they have effectively engineered a stable bactericidal 
surface [228, 229]. 
The clinical effectiveness of the aforementioned systems is most likely limited to 
infections caused by microorganisms that are sensitive to the specific antibiotic that has 
been coupled. It is also critical to be aware that, as previously mentioned, virulent 
strains of certain pathogens do not just colonize implant surfaces, but they are also 
capable to internalise within cells of the connective tissue. This occurrence is especially 
important in revision surgeries. Under such circumstances it is crucial to make use of 
antibiotics able to enter the membranes of eukaryotic cells and therefore reach 
intracellularly hidden bacteria. Otherwise, bacteria will survive all treatments well 
protected in the intracellular reservoir, ready to restart the infection once the local 
concentration of antimicrobial agent in the interstitial milieu will have lost its efficacy 
[80, 163, 217]. 
With the increasing number of antibiotic-resistant microorganisms, antimicrobial 
peptides (AMPs) are an extremely interesting group of anti-infective agents and 
currently sought as the next generation of antibiotics. AMPs are natural and 
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evolutionary conserved components of the innate immune system of all multicellular 
organisms to protect them against invading microorganisms [230]. Eukaryotic AMPs 
are small (10-50 amino acids), cationic and contain both hydrophobic and hydrophilic 
parts [231]. With a broad-spectrum of activity, not only against bacteria but also against 
certain viruses and fungi, their microbicidal action can be rapid through a number of 
different ways. Available data indicates that they act predominantly by disrupting the 
integrity of cell membranes through a strong electrostatic interaction between AMPs 
cationic residues and the negatively charged bacterial membranes, leading to instability, 
pore formation, osmotic changes and bacterial lysis [232-236]. However, an increasing 
number of peptides have also been described as acting on intracellular targets in 
bacteria, inhibiting protein or cell-wall synthesis or interactions with deoxyribonucleic 
acid (DNA) or ribosomal ribonucleic acid (rRNA) [237]. Accordingly, AMPs may 
represent excellent coating agents on a range of medical devices. They are far less 
susceptible to the development of pathogen resistance compared to conventional 
antibiotics, exhibit rapid and broad-spectrum killing profiles, inclusive against 
antibiotic-resistant bacteria, and are effective at low concentrations [230, 238-241]. The 
challenge remains being the immobilization of peptide molecules while keeping their 
accessibility and durable activity towards the surrounding bacterial cells [242]. 
Kazemzadeh-Narbat et al [243] coated the surface of titanium substrate with a thin layer 
of micro-porous calcium phosphate loaded with Tet 123 (a highly potent broad-
spectrum AMP) and found that the resulting coatings were able to kill both S. aureus 
and P. aeruginosa within 30 minutes of exposure and the coatings were absolutely non-
toxic toward osteoblast-like cells. In this scope, several other works can be found on the 
literature [244-248]. Therapeutic applications of AMPs are currently unavailable. 
Potential local toxicity, allergy, susceptibility to proteases and pH changes, high cost of 
peptide production constitute the main limitations associated to the use of AMPs [241, 
249, 250]. Nevertheless, AMPs are evoking increasing interest and are inspiring the 
production of new synthetic compounds in an attempt to overcome these drawbacks and 
optimise the bactericidal activity [235, 251, 252]. 
In the large group of natural polymers, chitosan (CS), derived from chitin, is 
noteworthy due to its intrinsic antibacterial and antifungal activities, albeit a weak 
bactericidal activity, which is usually enhanced at low pH. Different mechanisms for its 
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antibacterial activity have been proposed, such as electrostatic interaction, chelating and 
hydrophobic effect [145, 253]. CS-based biomaterials have other interesting 
characteristics such as biocompatibility, minimal foreign body reaction and the 
possibility to be moulded in various forms such as porous structures, which makes them 
suitable candidates for orthopaedic applications [254]. Over the last decades, with the 
intent to exalt its antibacterial properties, a broad family of CS derivatives has been 
developed aiming at antibacterial usage in biomedicine, either alone or in combination 
with other antimicrobial substances like antibiotics or AMPs [253, 255-257]. Among 
recent researches, quaternised chitosan-loaded bone cement was able to prevent biofilm 
formation of Staphylococcus, including antibiotic-resistant strains, on the surface of 
bone cement, and down-regulates expression of genes encoding essential enzymes for 
biofilm biosynthesis, as well as enzymes responsible for antibiotic-resistance [258]. 
An innovative approach goes through the enhancement of body’s natural 
defence systems to fight pathogens, thereby enhancing resistance to infection. 
Therefore, immunomodulatory proteins as chemokines are interesting anti-infective 
agents. In the early stage of infection, macrophages constitute the primary line of innate 
immune defence against most pathogens. In order to attract macrophages to the site of 
infection, one possible strategy is to deliver essential chemo-attractant proteins in the 
peri-prosthetic site. Among all the macrophage-recruiting chemokines, monocyte 
chemo-attractant protein-1 (MCP-1) is the most important for monocyte/macrophage 
recruitment in infection and inflammation [259, 260]. Based on this knowledge, Li et al 
[261] developed MCP-1 and interleukin-12 p70 (IL-12 p70) nanocoatings on 
orthopaedic implants and determined their anti-infection effectiveness using an open 
fracture infection model. The authors found that local MCP-1 therapy reduced S. aureus 
infection and influenced white blood cell populations while local IL-12 p70 treatment 
had a more profound effect on preventing S. aureus infection. Ultimately, this study 
demonstrates that this type of approach has therapeutic relevance in circumstances of 
impaired fracture healing in which macrophage performance is suboptimal. 
Still considering the immune system, nitric oxide (NO) is a potent antimicrobial 
molecule produced by macrophages, among others cells, as part of the natural immune 
response to infection [262]. NO is a strong oxidizing agent capable of targeting 
important structures within bacteria cells, including DNA and proteins, after diffusion 
32 
 
across their cell membranes. Oxidation of DNA by NO directly or indirectly by a 
multitude of reactive intermediates is capable of inducing irreparable damage by 
breaking the DNA strand [111]. NO reaction product peroxynitrite has also been 
implicated in cell membrane destruction by lipid peroxidation [263]. This effect may 
compromise cell attachment and thereby contribute to lower levels of bacterial 
adhesion. Therefore, the use of NO release as an antibacterial agent to reduce the 
infection around implants has been proposed. For example, Nablo et al [264] has 
examined the benefits of NO-releasing sol-gels as potential antibacterial coatings for 
orthopaedic applications, and they observed that the adhesion capabilities of P. 
aeruginosa, S. aureus, and S. epidermidis are diminished in the presence of a low-level, 
surface-localized NO flux at both ambient and physiological temperature. Later on, the 
same group confirmed the ability of NO-releasing xerogels to reduce the initial adhesion 
of P. aeruginosa under dynamic flow conditions. NO release was also able to kill 
adhered bacteria in a dose-dependent fashion over extended periods [265]. One step 
ahead, Charville and colleagues examined the efficacy of NO-release to prevent 
bacterial adhesion in the presence of an adhesion-promoting protein layer. The authors 
found that NO release from xerogel polymer surface reduced S. aureus, S. epidermidis 
and E. coli adhesion, even in the presence of pre-adsorbed fibrinogen [266]. Additional 
works based on the NO-releasing materials can be found in the literature [267-269]. 
Despite the exciting results, it is important to finely tune the beneficial and toxic effects 
of NO, which is active at concentrations as low as the picomolar and nanomolar 
produced by immune system [270]. 
The aforementioned approaches are a number of potential tools for biomedical 
engineers to develop the next generation of biomaterials aiming the prevention of initial 
microbial adhesion and, therefore, the subsequent implant-associated infection. 
Although, fighting against initial adhesion is not always sufficient to avoid biofilm 
development. The progress in the knowledge of the molecular mechanisms involved in 
the physiology of biofilm formation of different microorganisms has recently made 
available new opportunities to contrast the establishment of biofilms on biomaterial 
surfaces [112, 271-274]. Biofilm disruption could per se have limited efficacy in the 
prevention of infections, but the combination of anti-biofilm strategies with the delivery 
of conventional antimicrobials agents may have promising synergistic effects. 
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A wide range of substances that affect specific mechanisms involved in biofilm 
formation have been identified and can be either grafted on biomaterial surfaces or 
released by appropriate systems. These active substances include molecules with 
different action mechanisms: enzymes capable of selectively degrading biofilm EPS 
(e.g., dispersin B or deoxyribonuclease I) exposing sessile microbial cells to antibiotics 
as well as to the host immune defence; bactericidal molecules capable of killing even 
metabolically quiescent bacterial cells within biofilms (e.g., lysostaphin, certain AMPs); 
molecules interfering with the QS system and inducing biofilm dispersion (e.g., 
furanones); molecules down-regulating the expression of biofilm EPS (e.g., N-
acetylcysteine) or anyway reducing biofilm metabolism (e.g., hamamelitannin). Due to 
the diverse mechanisms of biofilm regulation that characterise different microbial 
genera and species, these substances often do not exhibit a broad spectrum of activity. 
Nevertheless, some of them selectively target staphylococcal species known to represent 
prevalent aetiological agents of implant-related infections. In view of the selectivity of 
their action, these molecules are generally expected to have a low impact on host cells 
and tissues [86, 275, 276]. 
The clinical potential of some of these molecules has already been estimated. 
For instance, dispersin B (DspB) is able to dissolve the staphylococcal ECM [276]. 
Several studies have demonstrated the synergistic antimicrobial and anti-biofilm activity 
between DspB and a large number of agents including cefamandole nafate [277], 
sodium dodecyl sulphate [278] and triclosan [279]. Accordingly, further 
characterization of these polymer-DspB-antibiotic systems sounds promising. Another 
promising enzyme is lysostaphin (LS). LS is an endopeptidase that disrupts the 
pentaglycine cross-linking bridges in the cell walls of staphylococci, especially on S. 
aureus, making their action highly active against both actively growing and quiescent 
bacteria, even on antibiotic resistant strains. Wu et al [280] found that LS is effective 
against planktonic S. aureus within minutes, as well as against S. epidermidis, albeit at 
higher concentrations. Additionally, the authors demonstrated that LS disrupted both S. 
aureus and S. epidermidis biofilms in vitro. In another study, Shah et al [281] observed 
that LS-coated catheters prevented biomaterial colonization by several strains of S. 
aureus, and the activity was maintained for at least 4 days. Concerning LS 
biocompatibility, Rawson et al [282] found that LS was biocompatible within the 
34 
 
reported biofilm inhibitory concentration ranges and supported osteoblast 
differentiation. 
The QS system comprises several molecules that can be potential clinical targets 
since QS is known to be crucial for survival of biofilm bacteria. It is a system mediated 
by small signaling molecules, called autoinducers. Different classes of autoinducers are 
involved in QS such as oligopeptides in Gram-positive bacteria and N-acyl homoserine 
lactones (AHLs) in Gram-negative bacteria. There is also a family of autoinducers 
named autoinducer-2 (AI-2) which are present in both Gram-negative and Gram-
positive organisms [130, 283, 284]. Deletions or inhibitions of this system obviated the 
whole process of biofilm formation for bacteria. Potent inhibitors of Gram-negative QS 
are the halogenated furanone and related synthetic derivatives that interfere with the QS 
by fixing on the binding site of AHLs [285, 286]. Alternatively, Baveja et al physically 
adsorbed a furanone on polymer materials while Hume et al covalently bound furanones 
to polymers commonly used for medical devices, and both studies have showed 
promising results, in vitro and in vivo, about furanones potential as a coating for 
biomaterials to control infection also caused by S. epidermidis [287, 288]. Similarly, 
strong inhibitors of Gram-positive QS were identified specifically RNAIII-inhibiting 
peptide (RIP). Several works have assessed the in vitro and in vivo efficacy of RIP 
[289-291]. For instance, bone cement beads loaded with RIP were implanted in rats and 
were able to prevent MRSA infection [292]. Overall, QS inhibitors and antagonists 
represent a promising strategy to counteract microbial adaptation to the host 
environment and the establishment of infectious processes [127, 293]. This knowledge 
from biofilm microbiology will be available for use in orthopaedics, and a detachment 
signal that triggers the natural detachment of cells from pre-formed biofilms also may 
be available in the near future [294]. 
Similar to the use of enzymes, most of these biofilm inhibitors prevent biofilm 
formation and restrict bacteria to the planktonic mode-of-growth, in which they are 
susceptible to host defences and antibiotics. Thus, their inclusion in coatings for 
orthopaedic devices would early interfere with QS system but an additional agent with 
antibacterial activity would improve the effectiveness of such approachs. Furthermore, 
special attention should be given to approaches based on biofilm disruption due to the 
resulting entrance of bacteria or groups of bacteria release from the biofilm into 
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circulation. These bacteria may not belong to either the planktonic or the biofilm phase 
and consequently may have a different pattern of antimicrobial susceptibility. A very 
interesting work by El-Azizi et al [116] showed that bacteria in the disrupted biofilms 
were as resistant as those in the intact biofilms at the minimum inhibitory 
concentrations of the antibiotics. At higher concentrations, bacteria in the disrupted 
biofilms were significantly less resistant than those in the intact biofilms but still more 
resistant than the planktonic cells. Therefore, the difficulty in treating the infections 
related to medical devices may not only be due to lack of eradication of the cells in the 
biofilm phase, but also due to resistance of bacteria disrupted from the biofilm. Even a 
combinatory therapy may be carefully evaluated. 
 
3.2.3. Alternative approaches 
The potential applicability of alternative ‘biologic weapons’ to prevent implant-
related infections has been explored. One of these approaches is the enormous group of 
natural products. Natural products have proven to be highly efficient for the treatment of 
infections and, not surprisingly, the variety of drugs based on natural products is 
enormous. There are drugs with broad and narrow spectra for oral, topical or parenteral 
administration and with activities against almost all known pathogens. Therefore, the 
search for antimicrobial agents able to inhibit bacterial biofilm formation can also be 
extended to natural substances [295, 296]. However, their complex composition may 
impair the straight clinical application. Further studies are still needed to have a clear 
understand of their mechanism of action, albeit the presence of numerous compounds in 
their composition suggests that their activity is probably not attributable to one specific 
mechanism but results from a combination of several mechanisms involving synergic 
effects [251]. 
Another ‘biologic weapon’ that has gained renewed interest with the increased 
prevalence of antibiotic resistance is bacteriophage therapy [297, 298]. Bacteriophages 
are viruses that specifically infect bacteria. In particular, lytic phages bind to a 
membrane receptor, introducing phage DNA into the cell. This DNA is replicated and 
translated by the host bacterium, leading to phage replication, progeny assembly, 
bacterial lysis, release of progeny, and phage propagation to surviving bacteria [299]. 
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The use of phages dates back to the first decades of the 20
th
 century however, nowadays 
has increasingly been explored even for the prevention of implant-related infections 
[300, 301]. Attempts have been made using either the lytic bacteriophages alone [302] 
or in combination with an antibiotic drug [303]. For instance, Yilmaz et al [304] 
performed an in vivo study to assess if bacteriophages would be effective against 
biofilm-forming bacteria and these authors got to the conclusion that the combination of 
bacteriophage treatment with an appropriate antibiotic regime helped to dissolve the 
biofilm of both MRSA and P. aeruginosa. Overall, bacteriophages are inherently non-
toxic and have minimal impact on the normal healthy flora. They have good cell-
penetrative ability, so can readily disrupt and lyse biofilm cells [300]. Nevertheless, the 
application of phages for infection prophylaxis presents some limitations and drawbacks 
such as: phages generally exhibit narrow spectrum of activity; pre-exposures of the 
immune system to the phages can cause virus inactivation; safety concerns have been 
expressed for the internal use of high titres of phages, which could expose the patient to 
health risks still not totally explored; the procedure for coating the implant surface has 
to preserve intact phage stability and infectivity; and ultimately, in nature phages are 
implicated in the horizontal spreading of virulence and antibiotic resistance genes 
among bacteria [305]. To overcome these drawbacks bioengineered phages are a 
possibility [306]. For instance, engineered phages able to express DspB were 
successfully tested against E. coli biofilms [307]. Through these approaches, phages can 
be used both to dissolve the biofilm matrix and to kill microbial cells within the biofilm.  
In a different approach, but with the same target, vaccines against appropriately 
selected patterns of bacterial adhesins appear an interesting and potentially effective 
control strategy since they could prevent initial bacterial adhesion to biomaterials [308]. 
The critical problem for vaccine development is the identification of a relevant antigen 
that is present in the planktonic and biofilm state of most clinical strains [309]. To 
overcome this issue, adhesin-targeting vaccines could be also assembled with others, to 
target diverse virulence factors, such as biofilm antigens or surface proteins other than 
adhesins, and thus to potentiate and expand their efficacy [310]. In this context, Brady 
et al [311] were able to generate a multicomponent vaccine using biofilm-specific 
antigens. The results obtained indicate that when vaccination was coupled with 
vancomycin treatment in a biofilm model of chronic osteomyelitis in rabbits, clinical 
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and radiographic signs of infection significantly reduced by 67 and 82%, respectively, 
compared to infected animals that were either treated with vancomycin or left untreated. 
In contrast, vaccination alone resulted in a modest and non-significant decrease in 
clinical (34% reduction) and radiographic signs (9% reduction) of infection, compared 
to non-vaccinated animal groups untreated or treated with vancomycin. It is not unfair 
conclude that the complexities of the biofilm architecture, with multiple microbiological 
communities and with various sites within the communities that can express different 
proteins required for survival, makes the development of a effective anti-biofilm 
vaccine a considerable challenge. 
 
3.3. Multifunctional surfaces 
The development of surfaces with multiple functionalities, for example both 
antibiofouling and bactericide properties, is quite appealing. In this framework, Gao et 
al [312] developed a specially structured infection-resistant coating on implants based 
on covalently grafted hydrophilic polymer brushes conjugated with an optimized series 
of AMPs. The polymer brush tethered AMPs showed excellent broad spectrum 
antimicrobial activity, as well as biofilm resistance in vitro. The biofilm resistance of 
the coating was attributed to the combined effect of polymer structure and the presence 
of AMPs, and the effect was correlated to hydrophobic/hydrophilic character of the 
coatings. In vivo studies demonstrated that the coatings were able to protect from 
bacterial infection and, the AMPs conjugated polymer coatings, were non-toxic to 
mammalian cells. Another interesting example is the work of Fullenkamp et al [189]. 
They synthesized a water-soluble PEG polymer that contain reactive catechol moieties 
which were then oxidized with silver nitrate, leading to covalent cross-linking and 
hydrogel formation with simultaneous reduction of Ag (I). Hydrogels were found to 
inhibit bacterial growth, consistent with the well-known antibacterial properties of 
silver, while not significantly affecting mammalian cell viability. In addition, thin 
hydrogel films were found to resist bacterial attachment, consistent with the 
antibiofouling properties of PEG. Immunotherapy (i.e., clinical delivery of externally-
derived antibodies) may also be a strategy to design multifunctional surfaces. Treatment 
with exogenously-supplied immunoglobulin G (IgG) has been shown to diminish the 
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severity of infections and reduce bacterial adhesion to model surfaces. IgG opsonisation 
(i.e., antibody recognition of and binding to bacterial cell-surface antigens) inhibits 
bacterial adhesion by blocking cell-surface attachment factors or mechanism of 
transport (e.g., flagella); or targets them for phagocytic destruction by immune system 
components including neutrophils, monocytes, and macrophages [313-317]. Rojas et al 
[318] work describes the release of IgG from hydrophilic polyurethane hydrogel 
coatings and they found that these coatings were effective in reducing the adhesion of E. 
coli, which indicate that pathogen colonization and virulence in implant sites and on 
biomaterial devices could benefit from these two-way approaches. 
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ABSTRACT 
Hydroxyapatite (HA) is a biocompatible and bioactive synthetic material for biomedical 
applications as it binds to bone and enhances bone tissue formation. Particularly, 
nanophased HA can mimic the dimensions of constituent components of natural tissues; 
can modulate enhanced osteoblast adhesion and resorption with long-term functionality 
of tissue engineered implants. However, HA does not inhibit bacteria from adhering 
onto its surface, and this has implications in the bone healing process required for 
patient recovery, since infection can lead to the implant failure. In the present work a 
composite that combines the favorable biological characteristics of nanohydroxyapatite 
(nanoHA) and, simultaneously, possesses antimicrobial activity as expressed by ZnO 
was synthesized. To determine whether the size of ZnO particles was playing an 
important role in inhibiting bacterial growth, ZnO particle of different sizes (from the 
microscale down to the nanoscale) and concentration were incorporated into nanoHA 
and tested. The composite samples were characterized by SEM, FT-IR, XRD, XPS and 
zeta potential. The antibacterial activity of the composites was investigated, as well as 
the biofilm formation, using both Gram-positive (Staphylococcus aureus) and Gram-
negative (Escherichia coli) microorganisms. The characterization revealed that ZnO 
particles were dispersed homogeneously within the nanoHA matrix. The composites 
antibacterial activity increased with decreasing ZnO particle size and increasing 
concentration. Biofilm formation tests revealed that the nanoHA-ZnO composites 
exhibit a strong effect against the common pathogens S. aureus and E. coli. 
 
Keywords: nanohydroxyapatite, zinc oxide, composite, antibacterial, biofilm 
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1. INTRODUCTION 
Hydroxyapatite is the most used calcium phosphate to be applied in implants due 
to its structural and chemical similarity with bone mineral component. It is highly stable 
in body fluids and is known for its exceptional biocompatibility, bioactivity, 
osteoinduction, and osseoconductivity properties [1], therefore it has been widely used 
clinically for coating metallic implants or filling small bone defects. Compared to 
conventional ceramic formulations, nanophased hydroxyapatite exhibits 
physicochemical characteristics similar to those of bone nanocrystals [2, 3]. The 
surfaces of these materials are generally designed to encourage tissue adherence, 
eventually leading to tissue or osseointegration but, unfortunately, this feature may also 
encourage bacterial adhesion. About half of the two million cases of nosocomial 
infections per year in the US are associated with indwelling devices [4]. Among 
surgical site infections, those related to implanted orthopaedic devices are of great 
relevance for public health due to the increasing number of aged and disabled patients 
requiring this type of surgical interventions [5]. Despite the low risk of infection, 
estimated to be in the range of 0.5%-5% for total joint replacements, they must be 
considered highly significant due to the serious consequences, which include prolonged 
hospitalization with systemic antibiotic therapy, several revision procedures, possible 
amputation, and even death [4, 6]. Such infections are difficult to treat with antibiotics 
because the bacteria causing the infection form biofilms on the implant surface. Once a 
biofilm has formed, the bacteria inside the biofilm are embedded in a polymeric matrix, 
protected from phagocytosis and antibiotics [7]. For this reason, a number of strategies 
for device-related infections prevention has been developed. Moreover, the increase in 
infections attributed to multi-drug-resistant Staphylococcus aureus has led to a growing 
interest in identifying and developing new strategies to reduce bacteria activity without 
the use of antibiotics [8]. The antibacterial agents can be classified into two categories 
according to their chemical composition: organic and inorganic. Organic antimicrobial 
agents are often less stable, particularly at high temperature or pressure, exhibit high 
decomposability and short life expectancy. On the other hand, inorganic antibacterial 
materials are robust and durable, and consequently have the key advantages of 
improved safety and stability [9-12]. As a consequence, inorganic materials such as 
metal and metal oxides have attracted attention due to their ability to resist harsh 
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process conditions. Among the metal oxides, zinc oxide (ZnO) has been shown to 
naturally reduce the activity of a wide range of bacterial strains, pathogenic and 
nonpathogenic, without the use of antibiotics [13, 14]. Several studies suggest that 
different morphologies (particle size and shape) and concentration of ZnO have 
different degrees of antibacterial activities [9, 10, 13, 15-17]. However, the mechanism 
of the antibacterial activity of ZnO is complex and still not completely understood, with 
different effects been suggested [8, 9, 11, 18-22]. The aim of the present research was to 
synthesize a composite that combines the favorable biological characteristics of 
nanohydroxyapatite (nanoHA) and, simultaneously, possesses antimicrobial activity as 
expressed by ZnO. Our attention was focused both on producing and characterizing 
nanoHA-ZnO composites and on evaluating the influence of ZnO particle size and 
amount on the bacterial activity and biofilm formation against a Gram-positive bacteria 
Staphylococcus aureus and a Gram-negative bacteria Escherichia coli, which are 
frequent etiologic agents on biofilm-related device-related infections [6, 23]. 
 
2. MATERIAL AND METHODS 
2.1. Synthesis of nanoHA-ZnO composites 
Zinc oxide powders were purchased from Sigma-Aldrich and used as received. 
The powders sizes given by the manufacturer were: particle size <1 µm, <100 nm and 
<50 nm. The composite samples were prepared by mixing ZnO powder with nanoHA 
(nanoXIM·HAp202; Fluidinona S.A., Portugal) at weight percentages (wt %) of 0, 2, 10 
and 25%. The composite powders were subsequently pressed as cylindrical samples of 
10 mm diameter in an uniaxial press (Mestra Snow, P3) under optimum pressure of 20 
bar [24]. NanoHA ceramics are very fragile materials if not adequately heat-treated, as 
are most ceramic materials, therefore two different heat-treatments were applied based 
in a previous work [25], namely 830 and 1000ºC, with a 15-min plateau and applying a 
heating rate of 20ºC min
-1
. The sintering cycle was completed with a natural cooling 
process inside the furnace (Commodore II, VPF, Jelenko). 
 
72 
 
2.2. Physicochemical characterization of nanoHA-ZnO composites 
The samples surface morphology was analyzed using a scanning electron 
microscope (SEM; FEI Quanta 400 FEG/ESEM) under 2500x magnification, with 15 
kV accelerating voltage. Carbon tape was used to fix samples to aluminum stubs and the 
samples were sputter-coated (SPI-Module) with a thin conductive film of Au-Pd alloy. 
The X-ray diffraction (XRD) measurements were performed with a X-ray 
diffractometer (Bruker DRX-Linxeye) using Cu K radiation ( = 1.540 Å), in a 2θ 
range from 25º to 70º. Distances between peaks were compared to the JCPDS 5-0664 of 
the International Center for Diffraction Data to determine crystalline structures. 
Chemical characterization was performed by Fourier transformed infrared spectroscopy 
(FT-IR) with a Perkin-Elmer 2000 FT-IR spectrometer. Measurements were performed 
with pressed discs made using potassium bromide (KBr) powder. The FT-IR spectra 
were collected between the wavenumber of 4000-400 cm
-1
 with one hundred scans 
accumulated per sample. Surface chemical composition analysis was performed by X-
ray photoelectron spectroscopy (XPS) using an ESCALAB 200A, VG Scientific (UK) 
with PISCES software for data acquisition and analysis. For that purpose, an achromatic 
Al (K) X-ray source operating at 15 kV (300 W) was used. Spectra analysis was 
performed using peak fitting with Gaussian-Lorentzian peak shape and Shirley type 
background subtraction (or linear taking in account the data). As a final analysis, zeta 
potentials were determined from streaming potential measurements with a commercial 
electro kinetic analyzer (EKA) (Anton Paar GmbH, Austria). The streaming potential 
was measured using Ag/AgCl electrodes installed at both ends of the streaming channel. 
The electrolyte used was 1 mM KCl and the experiments were performed at 25ºC. The 
mashed composites were placed on a cylindrical powder cell and the streaming potential 
was measured while applying an electrolyte flow in alternating directions and pressure 
ramps from 0 to 200 mbar. For each material, an average of at least three measurements 
was reported (three in each flow direction). 
2.3. Microorganisms and culture conditions 
The microorganisms used in this study were Staphylococcus aureus ATCC 
25923 and Escherichia coli ATCC 25922. Microorganisms were kept at -70ºC in a 
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solution containing 70% tryptic soy broth (TSB; Liofilchem, Italy) and 30% diluted 
glycerol. For each experiment the bacteria were freshly prepared by inoculating the 
frozen bacteria suspension onto nutrient agar (NA; Liofilchem, Italy) for 24 h at 37ºC. 
Stationary phase cells were obtained by incubating two to three colonies, from the NA, 
in 5 mL of TSB for 18h at 37ºC and 150 rpm. 
2.4. Antibacterial activity of nanoHA-ZnO composites 
To study the antimicrobial activity of nanoHA-ZnO composites, changes in the 
growth of each bacterium, incubated in TSB, in the presence of the composites were 
investigated. Overnight cultures, containing the bacteria on stationary phase, were 
inoculated into 2 mL of fresh TSB, in order to obtain an initial suspension of 10
5
 colony 
forming units (CFU) mL
-1
. The composite samples and pure nanoHA (control material), 
previously sterilized by dry-heat (180ºC, 1 h), were added to the test tubes and 
incubated in a constant-temperature shaker at 150 rpm and 37ºC. A tube without any 
biomaterial was used as a positive control. Negative controls were obtained by 
incubating the biomaterial in TSB without adding any bacterial cells. After 24 h of 
bacteria culture incubation, the optical density of these suspensions was measured on a 
microplate reader (Stat Fax 3200, Awareness Technology Inc.) at 545 nm and the 
background (turbidity due to growth medium and light-scattering properties of the 
nanoparticles) was eliminated by taking blank readings. Three replicate tubes were 
prepared for each material sample. 
2.5. Biofilm formation on nanoHA-ZnO composites 
The anti-adhesive potential of nanoHA-ZnO composites was evaluated by 
biofilm formation studies. Overnight TSB cultures containing the relevant bacterial 
strain were used to prepare a suspension with a turbidity equivalent to 0.5 McFarland 
standard (ca., 10
8
 CFU mL
-1
), then diluted in TSB to 1/100 (obtaining a 10
6
 CFU mL
-1
). 
The composite samples and pure nanoHA (control material), formerly sterilized by dry-
heat (180ºC, 1 h), were placed in tubes with 2 mL of the bacterial suspension previously 
prepared and incubated at 37C and 150 rpm. At the end of 24 h incubation, each 
material samples was rinsed twice with phosphate-buffered saline (PBS) and transferred 
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to tubes with 5 mL of sterile PBS and sonicated for two seconds, at 20 KHz in a 
sonicator (Sonopuls HD 2200, Bandelin, Germany) with a MS 73 probe. Serial dilutions 
of the sonicated solutions were prepared and inoculated in NA. The number of colonies 
was counted after overnight incubation at 37ºC and bacterial adhesion on the samples 
surface was expressed as number of adherent bacteria per mm
2
. Experiments were done 
in triplicate. 
2.6. Statistical analysis 
Experimental data was analyzed using IBM
®
 SPSS
®
 Statistics (vs. 19.0, SPSS, 
USA). The mean values were calculated and reported as the mean ± standard deviation 
(n=3). The one-way analysis of variance (ANOVA) followed by the post hoc Tukey 
HSD multiple comparison test was used to determine the significant difference (p < 
0.05). 
 
3. RESULTS AND DISCUSSION 
3.1. Physicochemical characterization of nanoHA-ZnO composites 
SEM images provide the direct observation of the composites surface 
morphology and, particularly, the back scattering images highlight the appearance of 
ZnO particles at the nanoHA surface (Fig.1). The primary ZnO particles tend to 
aggregate to form larger secondary particles uniformly disperse on nanoHA matrix. The 
ZnO nanoparticles are prone to aggregate and this may happen due to the large specific 
surface area [8, 26]. 
The 2 wt % ZnO (<100 nm) composite heat-treated at 1000ºC was chosen to 
illustrate the crystal structure of the ZnO particles in the nanoHA matrix (Fig. 2). The 
results of XRD analysis for other composite samples were similar to the one above 
referred, thus they are not presented. The characteristic diffraction peaks (100), (002), 
(101), (102), (110) and (103) are observed in all nanoHA-ZnO composites and they can 
be indexed to hexagonal ZnO (International Center for Diffraction Data, JCPDS 5-
0664). The presence of nanoHA phase is clearly recorded in all composite samples. The 
strong intensity and narrow width of diffraction peaks indicate that the resulting 
products were highly crystalline. 
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Figure 1. Back scattering electrons images collected by SEM of nanoHA-ZnO 
composites with different amounts of ZnO (<100 nm): 2 wt % (a, d), 10 wt % (b, e) and 
25 wt % (c, f), and heat-treated at two different temperatures: 830ºC (a-c) and 1000ºC 
(d-f). Scale bar 20 µm. 
 
Figure 2. XRD pattern of nanoHA-ZnO composite with 2 wt % ZnO (<100 nm), heat-
treated at 1000ºC. 
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Figure 3. FT-IR spectra of pure nanoHA (a) and nanoHA-ZnO composite with 10 wt % 
ZnO (<100 nm) (b), both heat-treated at 830ºC. 
Figure 3 depicts the FT-IR spectra of pure nanoHA and nanoHA-ZnO composite 
with 10 wt % ZnO (100 nm), both heat-treated at 830ºC. Comparable results were 
obtained for the other composites samples and heat-treatment (data not shown). It may 
be seen that the major peaks of nanoHA associated with PO4
3- 
(1098, 1039, 963, 604, 
575 and 479 cm
-1
) and OH
-
 (3575 and 636 cm
-1
) appear on both plots (Fig. 3 (a,b)). 
Compared with pure nanoHA, a new small absorption band in the range of 479 - 400 
cm
-1
 was found in the FT-IR spectra of nanoHA-ZnO composite (Fig. 3(b)), which was 
correlated to the stretching vibration of ZnO [27]. FT-IR and XRD results confirmed 
that heat-treated nanoHA-ZnO composites were phase pure and crystalline. 
 
Figure 4. XPS wide scan spectra of nanoHA-ZnO composite with 10 wt % ZnO (<100 
nm) heat-treated at 830ºC and the detected Zn 2p peak (inset) in the composites 
surfaces. 
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The antimicrobial activity strongly depends on the structure and stability of the 
different surface planes of ZnO, as well as the number of defects on the ZnO particles 
surfaces. Thus, XPS was used to study the ZnO particles in the nanoHA matrix once is a 
technique highly sensitive to the chemical composition and the environments of the 
elements in the material [10, 28]. The XPS wide scan spectra of nanoHA-ZnO 
composite (Fig. 4) shows the presence of Zn 2p, O 1s, Ca 2p, C 1s and P 2p core levels. 
The high resolution spectra of Zn 2p level is shown in Figure 4 (inset). The Zn peaks in 
the different surfaces are all in the same position and the binding energy peak of Zn at 
1022 eV belongs to ZnO. 
Table I. Zeta potential for nanoHA-ZnO composites with ZnO particle size 
100 nm, heat-treated at 830 and 1000ºC 
Sample 
(ZnO wt %) 
Zeta Potential (mV) 
830ºC 1000ºC 
0% -15.8 ± 2.0 -19.2 ± 1.1 
2% -16.9 ± 2.0 -15.9 ± 1.2
a
 
10% -16.4 ± 1.3 -11.2 ± 1.6
a
 
25% -12.0 ± 0.8
a
 -9.6 ± 0.4
a
 
a
 Significantly different from pure nanoHA (0%) (p < 0.05) 
Table I encloses the average zeta potential of pure nanoHA (0%) and nanoHA-
ZnO composites (with ZnO particle size 100 nm). All materials showed to be 
negatively charged after both heat-treatments. The presence of ZnO particles might be 
the main factor responsible for the observed change of zeta potential. The higher the 
ZnO amount, the less negatively charge will be the composite. 
3.2. Antibacterial activity of nanoHA-ZnO composites 
The effect of various nanoHA-ZnO composites on the growth of S. aureus and 
E. coli is presented in Figure 5.  
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Figure 5. Bacteria population (as a percentage of population on ceramic control) 
determined by optical density readings of S. aureus and E. coli suspension cultured for 
24 h with the composite samples at various weight percentages and with different ZnO 
particle size:<100 nm (A and C) and <50 nm (B and D). Material samples were heat-
treated at 830ºC (A and B) and 1000ºC (C and D). *p < 0.05, significant reduction 
compared to pure nanoHA (0%), according to Tukey HSD. 
Optical density data after 24 h of incubation indicated a significant reduction in 
total bacteria counts for bacteria cultured in the presence of the composites compared to 
bacteria cultured in the presence of pure ceramic samples. Similar results were obtained 
for composites with ZnO particle size of <100 nm and <1 µm (data not shown). These 
results also indicated that antibacterial efficiency increases with increasing ZnO amount 
for both studied bacteria. The data clearly suggest that, in comparison with pure 
nanoHA, composites formulated with ZnO nanoparticles with smaller sizes (50 nm) 
showed a significant growth inhibition at just 2 wt %, whereas for composites with 
relatively larger ZnO particles (<1 µm and <100 nm) the same effect was just observed 
at 10 - 25 wt % (depending on the particular bacterial strain). Similar profiles of 
antibacterial activity were obtained for both heat-treatments conditions. 
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3.3. Biofilm formation on nanoHA-ZnO composites 
The anti-adhesive properties of nanoHA-ZnO composites were also evaluated, 
since biofilm formation on materials surface is an undesired situation [6, 7]. With that 
propose, the bacteria were grown in contact with composite samples, with three 
different ZnO particle sizes and two distinct heat-treatments. After 24 h de number of 
viable cells attached on composite surface was evaluated. The obtained results for S. 
aureus and E. coli are shown in Figure 6 and 7, respectively. 
 
Figure 6. Biofilm formation of S. aureus on composite samples, at various weight 
percentages and different ZnO particles size, as determined by CFU mm
-2
, after 24 h of 
incubation. Material samples were heat-treated at 830ºC (A) and 1000ºC (B). All 
composite samples showed a significant reduction compared to pure nanoHA (0%) 
(*p<0.05, according to Tukey HSD). 
 
Figure 7. Biofilm formation of E. coli on composite samples, at various weight 
percentages and different ZnO particles size, as determined by CFU mm
-2
, after 24 h of 
incubation. Material samples were heat-treated at 830ºC (A) and 1000ºC (B). All 
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composite samples showed a significant reduction compared to pure nanoHA (0%) 
(*p<0.05, according to Tukey HSD). 
Compared with pure nanoHA, a strong and significant reduction on the biofilm 
formation was noticed, for the various composites. The reduction in biofilm formation 
was probably related to the reduction in the number of viable bacteria presented at the 
material surface. For all composites heat-treated at 830ºC, the reduction observed was 
above 60%, for both tested bacteria (86% reduction in biofilm formation, on average). 
The inclusion of 25 wt % ZnO (<50 nm) reduced biofilm growth by ~98% for S. aureus 
and 99% for E. coli, when compared to pure nanoHA (materials heat-treated at 830ºC). 
The composites heat-treated at 1000ºC also display a significant biofilm inhibition (62% 
reduction in biofilm formation, on average) nevertheless, the materials heat-treated at 
830ºC display higher anti-adhesive effect. Sintering at 1000ºC may have established 
stronger bonds, leading to ZnO particles entrapment by nanoHA matrix. Moreover, 
these results also suggested that the composite inhibitory effect had higher effect against 
S. aureus adhesion than against E. coli, in consistent with previous reports [19, 22] still, 
other studies observed the opposite effect [9, 29]. This differential effect may be 
attributed to different structure, chemical composition and thickness of the cell wall 
between S. aureus and E. coli [18, 22] as well as ZnO mechanism of action. 
The results obtained are in agreement with previous works reporting that ZnO 
particles are effective in inhibiting both Gram-positive and Gram-negative bacteria and 
the antibacterial properties of ZnO particles depends on the concentration and surface 
area [9, 11, 13, 15-18, 22, 29, 30]. This reduced bacteria activity may be due to a variety 
of mechanisms, including, the production of highly reactive oxygen species (ROS) 
(O2
2−
, OH
-
 and H2O2) on the surface of ZnO particles connected with fatal damage to 
the bacteria [9, 22]. However, several studies reported that the generation of H2O2 from 
the surface of ZnO is one of the primary effects that contribute to the antibacterial 
effect, which takes place via penetration of H2O2 through the cell walls. Because the 
hydroxyl radicals and superoxides are negatively charged particles, they cannot 
penetrate into the cell membrane and must remain in direct contact with the outer 
surface of the bacteria; on the other hand, H2O2 can penetrate into the cell [10, 16]. In 
addition, the generation of H2O2 strongly depends on the specific surface area of ZnO, 
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which results in higher antibacterial activity of the smaller nanoparticles [9, 10, 22]. 
These evidences can explain the strong effect observed in this study for composites with 
ZnO nanoparticles (50 nm). Furthermore, the increase of ZnO concentration in the 
composite results in a larger amount of H2O2 generated. The antibacterial activity 
exhibited by ZnO nanoparticles could also be due to the presence of soluble Zn
2+
 
formed when ZnO is suspended in solution. The solubility of metal oxide nanoparticles 
increases as their particle size decreases, and the enhanced activity of the smaller sized 
ZnO nanoparticles could also be due to the formation of dissolved Zn
2+
 ions [8]. 
Another possible explanation for the antibacterial effect is based on the abrasive surface 
texture of ZnO due to surface defects, which may cause damage and disorganization in 
the cell wall [10, 15]. And, if for one hand the anti-adhesive resistance of the bacteria to 
nanoHA-ZnO composites (Figs. 6 and 7) might be caused by an electrostatic repulsion 
resulting from identical charges at the surface of the composites (Table I) and bacteria 
(the overall charge of the bacteria at biological pH values is negative, because of the 
excess number of carboxylic and other groups [31]) which induced repulsion and 
prevented the contact and further adhesion [32]; it is also possible, on the other hand, 
that the ceramic composites surfaces might slightly degrade during the incubation 
period and some ZnO particles were released into the culture medium interfering with 
bacterial cell membranes, due to electrostatic attraction between ZnO particles and 
bacteria surface [20]. The above hypothesis may explain the great anti-adhesive 
properties display by the composites samples and also may explain the differences 
observed between both heat-treatments. 
 
4. CONCLUSION 
Implant infection remains as one of the major and often irreducible problems associated 
to the clinical use of biomaterials, demanding new therapeutic and preventive strategies. 
In this study the antimicrobial activity of ZnO powders was assessed, with particle sizes 
ranging from microns to nanometers, and at different weight percentages, when 
integrated into nanoHA. It was found that ZnO nanoparticles (50 nm) showed to be 
more effective, at a lower weight percentage, than the composites with other particles 
sizes, for both bacterial species and heat-treatments tested. The enhanced bioactivity of 
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smaller particles may be attributed to the higher surface area to volume ratio, which 
results in the generation of a larger number of active oxygen species which may cause 
fatal damage to microorganisms. Therefore, composites of nanoHA with ZnO 
nanoparticles should be further studied as a potential material to prevent 
microorganisms from attaching, colonizing, spreading, and forming biofilms in medical 
materials. 
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ABSTRACT 
Ceramic scaffolds are widely studied in the bone tissue engineering field due to their 
potential in regenerative medicine. However, adhesion of microorganisms on 
biomaterials with subsequent formation of antibiotic-resistant biofilms is a critical 
factor in implant-related infections. Therefore, new strategies are needed to address this 
problem. In the present study, three-dimensional and interconnected porous granules of 
nanostructured hydroxyapatite (nanoHA) incorporated with different amounts of zinc 
oxide (ZnO) nanoparticles were produced using a simple polymer sponge replication 
method. As in vitro experiments, granules were exposed to Staphylococcus aureus and 
Staphylococcus epidermidis and, after 24 h, the planktonic and sessile populations were 
assessed. Cytocompatibility towards osteoblast-like cells (MG-63 cell line) was also 
evaluated for a period of 1 and 3 days, through resazurin assay and imaging flow 
cytometry analysis. As in vivo experiments, nanoHA porous granules with and without 
ZnO nanoparticles were implanted into the subcutaneous tissue in rats and inflammatory 
response after 3, 7 and 30 days was examined, as well as their antibacterial activity after 
1 and 3 days of S. aureus inoculation. The developed composites showed to be 
especially effective at reducing bacterial activity in vitro and in vivo for a weight 
percentage of 2% ZnO, with a low cell growth inhibition in vitro and no differences in 
the connective tissue growth and inflammatory response in vivo. Altogether, these 
results suggest that nanoHA-ZnO porous granules have a great potential to be used in 
orthopaedic and dental applications as template for bone regeneration and, 
simultaneously, to restrain biomaterial-associated infections. 
 
Keywords: nanostructured hydroxyapatite, zinc oxide nanoparticles, porous granules, 
antibacterial activity, biocompatibility 
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1. INTRODUCTION 
In bone tissue engineering, the search for bone substitutes is still a challenge to 
researchers. In this framework, ceramic scaffolds are widely studied and are a key 
component providing support to cell adhesion, proliferation and, ultimately, ensuring 
structural support to the newly formed tissue [1, 2]. Macroporous structured granules 
are particularly useful, since those materials can fill irregularly shaped bone defects and 
patient-specific shapes, in orthopaedic or periodontal applications [3]. Among the 
various forms of calcium phosphate ceramics, hydroxyapatite (HA) has received 
considerable attention due to its excellent bioactive and osteoconductive properties as it 
bonds to bone and enhances bone tissue formation. Nanocrystalline synthetic HA in 
particular has superior functional properties due to its particle size, large surface area to 
volume ratio, reactivity, and biomimetic morphologies compared to the mineral phase 
of bone [4, 5]. However, rapid host protein adhesion to the implant and low vascularity 
in the area of trauma create a suitable environment for bacterial adherence and, as a 
result, implant surfaces can harbour bacterial infections in the form of biofilm [6]. Due 
to the increasing number of prostheses being implanted every year, infection of 
implanted material is a major complication for modern medicine, which results in high 
socioeconomic costs since the treatment is often prolonged and expensive. Extensive 
antibiotics treatment alone is usually only able to suppress, but not eliminate these 
infections because biofilm state protects the bacteria against antibiotics and host 
immune system, thus making revision surgery mandatory. However, each revision 
surgery bears an increased risk of yet another infection [7, 8]. In clinical practice, 
current strategies for the prevention and treatment of these infections include the use of 
antibiotic-loaded cements or localized antimicrobial delivery systems. However, one of 
the main drawbacks of these systems is the elution kinetics which usually exhibits a 
burst release of the adsorbed antibiotics in the first hours followed by a long-lasting 
phase of slow release at very low concentrations, below the minimal inhibitory 
concentration. Such behaviour indulges the emergence of drug-resistant bacterial 
strains. Moreover, antimicrobials are typically ineffective in penetrating pre-established 
biofilms [9]. As a result, there is an urgent clinical need to develop alternative infection-
resistant surfaces, beyond the use of antibiotics, as the main strategy to prevent the 
establishment of implant colonization and biofilm formation. In this regard, inorganic 
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materials like metal oxide are gaining significant scientific attention compared to 
conventional antibacterial agents [10-12]. Among them, zinc oxide (ZnO) is a 
prominent agent exhibiting a broad spectrum of antimicrobial activity [13]. Moreover, 
smaller particles, at nanoscale dimensions, with higher surface area, have further 
enhanced the antibacterial behaviour of ZnO [12, 14, 15]. Particularly, the authors’ 
previous report confirmed that two-dimensional nanoHA samples incorporated with 
ZnO (particles from the micrometer scale down to the nanometer range) had robust in 
vitro antibacterial activity, with an inverse relationship between particle size and 
antibacterial effect [16]. As a consequence, the challenge of the present study was the 
continued investigation of the natural antibacterial properties of ZnO nanoparticles 
when incorporated, at different concentrations, into nanostructured hydroxyapatite 
(nanoHA) for the development of scaffolds, specifically three-dimensional 
nanostructured porous granules. In vitro antibacterial activity against Staphylococcus 
aureus and Staphylococcus epidermidis was investigated, as both strains are known to 
be leading species of implant-related infections [8, 17]. In addition, the 
cytocompatibility of such composites were also evaluated towards osteoblast-like cells 
(MG-63). Further, using a subcutaneous rat insertion model, the inflammatory reaction 
and the in vivo antibacterial activity of nanoHA-ZnO granules were also investigated. 
 
2. MATERIALS AND METHODS 
2.1. Preparation of nanoHA-ZnO granules 
In order to obtain the nanoHA-ZnO porous granules, the polymer sponge 
replication method was adopted [18]. Initially, the composite powder were prepared by 
mixing as-received ZnO nanoparticles (<50 nm particle size, Sigma-Aldrich) with 
nanoHA powder (nanoXIM·HAp202; Fluidinova S.A., Portugal) at weight percentages 
(wt %) of 0, 0.5, 1, and 2. Then, four different slurries were prepared using the ratio of 
5:4.5:0.2 for powder (g), water (mL), and deflocculating agent (mL), respectively. 
Deflocculating agent (Dolapix CE-64, Zschimmer & Schwarz, Germany) was used for 
the composite suspension to reach the appropriate viscosity [19]. Polyurethane sponges, 
used as template, were impregnated with the slurries, gently squeezed to remove the 
exceeding suspension and dried at room temperature for 24 h. The infiltrated sponges 
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were heat-treated according to the following sintering cycle: heating rate of 1ºC/min 
with 1 hour dwelling time at 600ºC for the polyurethane sponge to burn out, followed 
by a heating rate of 4ºC/min with 1 hour dwelling time at 830ºC [16, 20]. The samples 
were cooled inside the furnace. Afterward, the scaffolds were cut with a sharp razor and 
sieved to obtained granules with sizes between 2 to 3 mm. Prior to biological 
experiments, the materials were sterilized by dry heat (180ºC, 2 h). 
2.2. Granules morphology 
The morphology of nanoHA porous granules with and without ZnO 
nanoparticles was characterized by scanning electron microscopy (SEM, FEI Quanta 
400 FEG ESEM) operated at 15 kV, and coupled to an energy dispersive X-ray analyzer 
(EDAX Genesis X4M) for elemental analysis. Thus, the granules were attached with 
Araldite
TM
 to an aluminium sample holder and sputter-coated with a gold-palladium 
conductive film (SPI-Module). 
2.3. Measurement of Zn-ion release from granules surfaces 
In order to measure the amount of zinc (Zn
2+
) released from the biomaterials 
surfaces, granules of pure nanoHA and nanoHA with 2% ZnO were immersed in ultra 
pure water for 1 and 3 days. After incubation, the supernatants were collected and 
analyzed by atomic absorption spectroscopy (AAS, Hitachi-Z8200 Polarised Zeeman). 
The ion concentrations were reported in units of parts per million (ppm). 
2.4. In vitro antibacterial activity 
In vitro antibacterial activity of nanoHA granules with and without ZnO was 
quantitatively evaluated against S. aureus ATCC 49230 and S. epidermidis ATCC 
35984 on 96-well plates. Initially, overnight cultures were diluted in tryptic soy broth 
(TSB, Liofilchem) and an aliquot of 200 µL of this bacterial suspension (10
4
 colony 
forming units (CFU)/mL) was added to each well, containing 10 mg of granules. After 
24 h incubation at 37ºC, the bacterial suspension, from each well, was collected and the 
planktonic bacteria were quantified by optical density (OD) at 545 nm with a 
microplate reader and by colony counts (CFU/mL), on nutrient agar (NA, Liofilchem) 
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plates. Then, the materials were carefully washed twice with saline solution (0.9% 
NaCl, JT Baker), to remove non-adherent bacteria, and the metabolic activity of sessile 
bacteria was assessed by Alamar Blue (AB) method. Briefly, 200 µL of TSB with 10% 
resazurin (Sigma-Aldrich) were added to each well and incubated for 3 h at 37ºC. AB is 
a redox indicator that both fluoresces and changes colour in response to chemical 
reduction. The extent of reduction is a reflection of bacterial metabolic activity. After 
incubation, the fluorescence was recorded using a microplate reader (excitation: 530 nm 
and emission: 590 nm). Five samples per group were used. 
2.5. In vitro cytocompatibility test 
For the in vitro cytocompatibility study, human osteoblast-like cells lineage 
(MG-63) were maintained in alpha minimum essential medium (α-MEM, Sigma-
Aldrich) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS, 
Gibco), 1% (v/v) penicillin-streptomycin (100 IU/mL penicillin and 2.5 µg/mL 
streptomycin, Gibco), and 1% amphotericin B (2.5 µg/mL, Gibco). Incubation was 
carried out in a humidified atmosphere of 95% air and 5% CO2 at 37ºC. Prior cell 
seeding, 10 mg of granules of pure nanoHA and nanoHA with 2% ZnO were pre-
incubated into 24-well plate, with complete medium for 1 h at 37ºC. Then, the medium 
was removed and the cells were seeded on the granules at a density of 5x10
4
cell/well. 
Subsequently, the culture plate was incubated for 1 and 3 days. To evaluate the cellular 
metabolic activity, cells were incubated with resazurin solution (0.1 mg/mL, Sigma-
Aldrich) for 3 h at 37ºC. Afterwards, the supernatant had the fluorescence intensity 
measured in a fluorimeter (excitation: 530 nm and emission: 590 nm, Synergy HT, 
BioTek). The experiment was performed in triplicate for each group. 
2.6. Apoptosis assay by Imaging Flow Cytometry 
The cytotoxic nature of nanoHA-ZnO granules was also studied. Thus, MG-63 
cells were seeded at concentration of 10
6
 cells/mL into 6-well culture plate. After 24 h 
(attachment phase), granules of pure nanoHA and nanoHA with 2% ZnO (10 mg) were 
added over the cells. Tissue-culture polystyrene (TCPS) wells, without any biomaterial, 
were used as negative control. Three replicas for each group were used. The following 
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incubation was carried out for 1 and 3 days. Afterwards, culture medium (containing 
dead cells) and adherent cells (detached with 0.5% of trypsin) were collected and the 
apoptosis assay was done according to the manufacturer (Annexin V-FITC Apoptosis 
Detection Kit, Sigma-Aldrich). Briefly, 10
6
 cell/mL were suspended in buffer with 
propidium iodide (PI, 0.5 mg/mL) and Annexin V-FITC solution (100 mg/ mL) at 37ºC 
for 30 min, in absence of light. The cells were immediately analyzed with imaging flow 
cytometry (Image Stream X Mark II, Amnis), by detecting the fluorescence emitted by 
PI (DNA - dead cells) and Annexin V (phosphatidylserine - apoptotic cells) in each 
event. A single-cell gate was used to exclude aggregated cells (doublets, triplets) and 20 
000 gated events were collected for each analysis. 
2.7. In vivo biocompatibility and infected pouch studies 
Forty male Wistar rats between 150 and 250 g (8 week-old, Charles River, 
Wilmington, MA) were employed for subcutaneous implantation of biomaterials (20 
animals were used for the inflammatory response and further 20 animals for the in vivo 
infected pouch with S. aureus). The studies were performed in accordance with Animal 
Ethical Committee and fulfilled all legal requirements (Process number 016825, DGV, 
Lisbon, Portugal). Surgical procedures were performed under standard aseptic 
conditions. Pre-operatively, rats were anesthetized by intraperitoneal injection of 
ketamine (80 mg/kg) and xylazine (10 mg/kg). Then, the dorsal area of each rat was 
shaved, disinfected and a 2-4 cm midline incision was created. Sharp and blunt 
dissections were used to develop two individual subcutaneous pockets distributed on the 
left and right side of the incision. The sterilized granules of pure nanoHA and nanoHA 
with 2% ZnO were moistened with physiologic saline solution (0.9% NaCl) and 
inserted bilaterally into the subcutaneous pockets. The dorsal incision was then closed 
with surgical staples. Post-operatively, the rats were subcutaneously administered saline 
solution (10-20 mL/kg) for fluid replacement. After recovery, the rats were housed in 
pairs and allowed to move in their cages without restriction. They were fed with 
commercial rat chow and water ad libitum. Three days, one and four weeks after 
surgery, the rats were euthanized with carbon dioxide asphyxiation. All samples 
(biomaterial and surrounding tissue) were explanted and gross examination was 
performed on each biopsy prior to fixation for histological analysis. 
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Same surgical procedures were conducted for the infected pocket model. Thus, 
after biomaterial implantation and closing the injury, pockets were inoculated with 0.5 
mL of a bacterial suspension of S. aureus ATCC 49230 at 10
4
 CFU/mL, in saline 
solution. The recovery and post-surgery treatments were done as described above. After 
1 and 3 days, the animals were euthanized as aforementioned and the biomaterials were 
carefully harvested with surrounding tissue under sterile conditions. The specimens 
were homogenized in saline solution for bacterial quantification. For that purpose, serial 
dilutions were made and inoculated onto NA plates. After 24 h of incubation at 37ºC, 
bacterial colonies were counted and the CFUs/mL were calculated. 
2.7.1. Histological analysis 
The collected specimens were fixed in 10% neutralized buffered formalin for 24 
h and then processed using a standard method. Briefly, fixed specimens were embedded 
in paraffin and were sectioned longitudinally with a microtome (5-µm of thickness). 
The sections were stained with hematoxylin-eosin (HE) for light microscopy 
examination. 
2.8. Statistical analysis 
Results were expressed as mean ± standard deviation. Statistical analysis was 
assessed by one-way analysis of variance (ANOVA), followed by multiple comparisons 
among groups using the Tukey HSD post hoc test (IBM
®
 SPSS
®
 Statistics, vs. 19.0). 
The data were considered to be significantly different when p < 0.05 was obtained.  
 
3. RESULTS 
3.1. Granules morphology 
The nanoHA granules, with and without ZnO nanoparticles, presented a 
heteroporous morphology with macro and micro-pores as well as vast pore 
interconnectivity under SEM visualization (Figs. 1A and B). High magnification images 
showed that nanoHA crystals aggregates, after the sintering treatment, strongly bond to 
each other and yet preserving the nano-size dimension (Fig. 1 C). The presence of ZnO 
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nanoparticles, as lighter spots, homogeneously dispersed in nanoHA substrate was 
highlight through backscattered electrons imaging (Fig. 1D) and further confirmed by 
EDAX spectra showing the presence of elemental Zn peak (Fig. 1E). 
 
 
Figure 1. Micro- and nano-structure of porous granules of nanoHA (A, B and C) and 
nanoHA with 2% ZnO (D) obtained by the polymer replication method. SEM images 
obtained by secondary electrons (A, B and C) and by backscattered electrons, at higher 
magnifications, to highlight ZnO nanoparticles dispersion on nanoHA substrate (lighter 
spots) (D), additionally confirmed by EDAX spectrum (E). Scale bar 500 µm (A), 100 
µm (B), 500 nm (C) and 1 µm(D). 
3.2. Zn-ion released from granules surfaces 
Elemental zinc released from granules surface of pure nanoHA and nanoHA 
with 2% ZnO, when immersed in ultrapure water, was measured by AAS. Results 
indicated that, for composite samples, the zinc amount slightly increased from 0.30 to 
0.38 ppm, from day 1 to day 3, respectively. For granules of pure nanoHA, as expected, 
zinc-ion was not detected in this supernatant. 
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3.3. In vitro antibacterial activity 
Prior to in vivo experiments, the in vitro antibacterial efficacy of nanoHA-ZnO 
porous granules was first validated. For this, the materials were inoculated with S. 
aureus and S. epidermidis and their bactericidal efficacies against planktonic and sessile 
bacterial growth were assessed, after 24 h incubation. Regarding S. aureus planktonic 
values, either by OD or CFU/mL, only nanoHA impregnated with 2% ZnO exhibited 
statistically significant antibacterial activity, with no bacterial growth on the culture 
plates (Fig. 2). Whereas for S. epidermidis a significant reduction in planktonic growth, 
assessed by agar plating, was observed for the three tested composites, when compared 
to pure nanoHA granules (Fig. 2). Furthermore, the metabolically active bacteria on 
material surface (sessile population) exhibited a concentration-dependent effect for both 
microorganisms (Fig. 3), with a significant reduction for the composites with 1 or 2% 
ZnO nanoparticles, comparatively to pure nanoHA granules. Noteworthy, the granules 
with 2% ZnO have enabled a complete inhibition of bacterial viability and therefore this 
was the composite selected for the subsequent experiments. 
Figure 2. Planktonic population of S. aureus and S. epidermidis cultured for 24 h with 
porous granules of nanoHA (control) and nanoHA with different amounts of ZnO 
nanoparticles. Quantification by OD and CFU/mL. *p < 0.05, significant reduction 
compared to control (0%). 
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Figure 3. S. aureus and S. epidermidis sessile population on nanoHA granules with 
different amounts of ZnO nanoparticles (as a percentage of sessile population on 
control), after 24 h incubation. Quantification by AB method. *p < 0.05, significant 
reduction compared to control (0%). 
3.4. In vitro cytocompatibility test 
The metabolic activity of MG-63 cells on porous granules of pure nanoHA and 
nanoHA with 2% ZnO nanoparticles was assessed by resazurin assay and is shown in 
Figure 4. The resazurin values of cells cultured with the composite were similar to those 
obtained for pure nanoHA granules after 1 day of culture. However, at day 3, the 
nanoHA-ZnO granules caused an inhibitory effect on MG63 cells, with a lower increase 
on cell metabolic activity, compared to the control. 
 
Figure 4. Metabolic activity of MG-63 cells cultured for 1 and 3 days on porous 
granules of pure nanoHA and nanoHA with 2% ZnO nanoparticles, estimated by 
resazurin assay. *p < 0.05, significantly different. 
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3.5. Apoptosis assay by Imaging Flow Cytometry 
To further confirm the mode of cell death induced by nanoHA-ZnO granules, 
MG-63 cells exposed to the materials for 1 and 3 days were analyzed by imaging flow 
cytometry using PI/Annexin V-FITC staining. As depicted in table I, nanoHA granules 
had no negative effect on osteoblasts. In fact, cells were more viable on this material 
when compared to control (TCPS) with low or even negligible percentage of apoptotic 
or dead cells. On the other hand, the cells incubated with nanoHA-ZnO granules had 
started the apoptotic process, expressed by the higher percentage of cells in early and 
late apoptosis, comparatively to the other groups. However, it is important to underline 
that, after 3 days of culture, the percentage of apoptotic cells, as well as dead cells had 
shown a tendency to decline along with an increase in the number of living cells.  
 
Table I: Apoptosis assay evaluated by image flow cytometry 
Day 
Control (TCPS) nanoHA nanoHA-ZnO 
Live EA  LA Dead Live EA  LA Dead Live EA  LA Dead 
1 88.4 0.7 1.5 9.3 99.5 0.2 0.0 0.3 79.6 13.6 3.1 3.4 
3 99.3 0.7 0.0 0.0 99.5 0.5 0.0 0.0 86.8 12.2 0.0 0.8 
EA: Early apoptosis; LA: Late apoptosis 
3.6. In vivo biocompatibility and infected pouch studies 
It should be noted that all surgical procedures performed went through without 
any accidents, and the animals recovered uneventfully from surgery and general 
anaesthesia. Their post-operative recovery was normal, and all surgical sites healed 
without complications. 
The in vivo biocompatibility evaluation of nanoHA granules with and without 
ZnO revealed further features than the in vitro analyses. During the explant of the 
subcutaneous implants intense new vascularisation could be observed surrounding both 
types of granules after 3 days of implantation. Additionally, microscopic examination of 
the specimens indicated considerable tissue regeneration and angiogenesis (Figs. 5 and 
6). On day 3, both implants elicited a normal acute inflammation response with 
recruitment of inflammatory cells namely macrophages, lymphocytes, and rarely giant 
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cells. After 30 days of implantation no signs of chronic inflammation instead, in the 
vicinity of the material, high density connective tissue was observed with the presence 
of fibroblasts and blood vessels (Fig. 6). 
 
 
Figure 5: Histological analysis of HE stained sections of porous granules of pure 
nanoHA and nanoHA with 2% ZnO nanoparticles, after 3, 7 and 30 days of in vivo 
subcutaneous implantation. Scale bar 100 µm. 
 
Figure 6: Histological analysis of HE stained sections of porous granules of pure 
nanoHA and nanoHA with 2% ZnO nanoparticles, after 3 and 30 days of in vivo 
subcutaneous implantation. M, material; F, fibroblasts; CT, connective tissue. Scale bar 
50 µm. 
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To access the antibacterial effect of the composite in vivo, an inoculum of S. 
aureus was injected along the porous granules of pure nanoHA and nanoHA with 2% 
ZnO nanoparticles, and after 1 and 3 days the number of CFUs isolated from the 
homogenized samples (biomaterial and surrounding tissue) was quantified. As depicted 
in Figure 7, after 3 days of trial, the number of bacteria retrieved from the nanoHA-ZnO 
implants was significantly lower than that on pure nanoHA biopsies, for which a 
bacterial proliferation was observed between days 1 to day 3. 
 
Figure 7: Number of viable S. aureus isolated from implanted porous granules of pure 
nanoHA and nanoHA with 2% ZnO nanoparticles, after 1 and 3 days of in vivo 
subcutaneous infection. *p < 0.05, significantly different. 
 
4. DISCUSSION 
The current goal for tissue engineering, in particular orthopaedic and dental 
research, is to produce high-quality bone substitute in vitro, capable to repair or replace 
bone tissue, that may be used as a clinical alternative to an autograft, the present ‘gold 
standard’ treatment [21]. However, the ultimate biomaterial should not only present 
high biocompatibility and bioactivity and appropriate mechanical properties but also 
antibacterial properties once biomaterial-related infections are a major threat to the 
current use of biomaterials. Infection seriously limits the healing and regenerative 
capacity of a tissue and remains a major limitation in the long-term utility of medical 
implants [22]. It is, therefore, crucial to identify an approach that might reduce bacterial 
growth without reducing mammalian cell functions. 
102 
 
Currently, several progresses have been made to use inorganic nanoparticles for 
biomedical applications. The advantage of using inorganic oxides is that they contain 
ions that are essential to humans and exhibit strong activity even when administered in 
small amounts [23]. Furthermore, they are much more stable and have a longer life than 
organic-based agents and, therefore, have superior safety and stability [11, 24]. 
Particularly, ZnO nanoparticles offer significant benefits for potential new 
nanotechnology-based biological applications, being already used in the cosmetic and 
sunscreen industry due to their transparency and ability to reflect, scatter, and absorb 
UV radiation, and as food additives [25]. Additionally, one of the most attractive 
features of these nanoparticles is their antibacterial activity, with several published 
reports confirming the efficacy of ZnO nanoparticle-based preparations as prophylactic 
agents against bacterial infections [26-28]. Thus, in order to provide antibacterial 
properties to a well-known biocompatible and bioactive ceramic nanoHA, which does 
not involve the use of antibacterial pharmaceutical agents, and with a clinically relevant 
morphology, three-dimensional nanostructured porous granules of HA incorporating 
small amounts of ZnO nanoparticles were produced. 
In order to develop this type of biomaterial for bone tissue engineering it is 
important to meet certain criteria not only in terms of chemical composition, but also in 
terms of physical characteristics such as high and adequately distributed porosity. As 
depicted in figure 1, the three-dimensional porous granules synthesized by polymer 
replication method exhibited the required interconnected macro and microporosity 
throughout the scaffold. Microporosity (pore sizes below 10 µm), visualised in the pores 
walls, is important for cell adhesion while macroporosity (pore sizes higher than 100 
µm) is essential for in vivo cell in-growth. In addition, the interconnected pore network 
allows better spatial organization for cell growth and extracellular matrix production, 
neovascularisation, higher levels of water and nutrients circulation as well as metabolic 
waste removal [1-3, 29]. Moreover, the granules nanofeatured surface produces a high 
surface area to volume ratio [18] and such morphological characteristic is known to 
increase selective protein and growth factors adsorption, promoting protein bioactivity, 
and improve subsequent tissue-forming cell functions leading to a better 
osteointegration in vivo [30-35]. Additionally, the observed nanoHA particles fusion 
obtained after the sintering treatment, is a very important feature because particles 
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detachment could cause significant problems, that is, free particles could migrate from 
the scaffold and induce an inflammatory response in the body; therefore, nanoparticles 
should never be released or rapidly dissolve [36]. Concerning ZnO nanoparticles, their 
high surface area, unique physiochemical properties, and improved surface reactivity 
[37] contribute to greater interactions with biological targets such as bacteria and host 
tissue [27, 38]. 
Several studies have shown that ZnO nanoparticles induce cytotoxicity in a cell-
specific and proliferation-dependent manner, with rapidly dividing cells being more 
susceptible than normal quiescent cells. For instance, Taccola et al findings confirmed 
the ZnO nanoparticles selective cytotoxic action on rapidly proliferating cells, whether 
benign or malignant [39]. In other study, Premanathan et al demonstrated that human 
myeloblastic leukemia cells (HL60) were more susceptible to ZnO nanoparticles than 
the normal peripheral blood mononuclear cells (PBMCs) and Akhtar et al also observed 
that ZnO nanoparticles induce apoptosis in cancer cells (human hepatocellular 
carcinoma HepG2, human lung adenocarcinoma A549, and human bronchial epithelial 
BEAS-2B), while causing no impact on normal rat astrocytes and hepatocytes [23, 40]. 
In the present study, a similar profile was observed. The metabolic activity of human 
osteoblastic cancer cells (MG-63) exibhited a delay in cell proliferation after 3 days 
exposure to nanoHA-ZnO granules (Fig. 4) and the imaging flow cytometry analysis 
provided evidences that ZnO nanoparticles may induce apoptosis (Table I). 
One of the primary mechanisms of nanoparticles toxicity, found for a diverse 
range of nanomaterials, is the free radical production. The sequential oxidation-
reduction reactions may occur on the nanoparticle surface to produce reactive species, 
in a size-dependent way [37, 41]. Collectively, the aforementioned studies indicated that 
the underlying molecular mechanism of ZnO nanoparticles toxicity might involve the 
generation of reactive oxygen species (ROS), which is currently the best-developed 
paradigm for nanoparticle toxicity. The ROS production exceeds the cell’s antioxidant 
capability resulting in oxidative stress, inflammation, and consequent irreparable 
damage to proteins, membranes, and DNA [37, 42]. Mitochondrial perturbation and 
DNA damage lead to the release of pro-apoptotic factors and, ultimately, programmed 
cell death. Sharma et al provides valuable insights into the mechanism of ZnO 
nanoparticles induced toxicity in HepG2 cell line [43]. However, mammalian cells are 
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able to limit toxicity and free radical damage due to a number of defences such as their 
antioxidant enzymes and their ability to phagocyte and dissolve nanoparticles, if free, 
by lysozomal fusion [37]. 
Similarly, the generation of ROS is also one mechanism proposed to explain 
their antimicrobial properties, enhanced by the greater specific surface area of 
nanoparticles [44]. The ROS production, like H2O2 or highly reactive hydroxyl radical 
and singlet oxygen, might trigger membrane lipid peroxidation and cause bacterial death 
[10]. As required, in the present study, a strong antibacterial effect against sessile 
bacterial growth was observed for granules of nanoHA with 2% ZnO (Fig. 3). Such 
effect is noteworthy once bacterial adhesion is the first and most important step of 
implant-related infection. Preventing bacterial adhesion could be a crucial way for its 
prevention [45]. Interestingly, at this wt %, ZnO only exhibited a low inhibition in cell 
growth with few apoptotic cells. Another potential mechanism of ZnO towards bacterial 
cells occurs through the leaching of zinc ions when the composite is suspended in an 
aqueous solution. The positively charged ions released into the medium can get 
attracted to the negatively charged cell membrane of bacteria by means of electrostatic 
interactions [46]. For instant, Seil et al observed a correlation between Zn ion released 
and antimicrobial activity [27]. However, in the present work, the measured 
concentration of zinc was found to be far lower than the minimum inhibitory 
concentrations identified by McCarthy et al or Zeelie et al against S. aureus (50 or 9 
µg/mL respectively) [47, 48]. Such results may point out that ROS might be the major 
mechanism of nanoHA-ZnO granules antibacterial effect, which is in good agreement 
with other reports [10, 28]. Therefore, direct contact between ZnO particles and 
biological cells is not essential for enabling ZnO antibacterial activity [10]. The 
advantage of this strategy over others, with traditional antibiotics, relies precisely on the 
entrapment of ZnO nanoparticles within nanoHA substrate rather than as a coating, 
which enables a greater retention of antibacterial effects over time, avoiding the typical 
burst effect frequently detected for adsorbed drugs. Moreover, a strong effect was 
obtained using small amounts of ZnO nanoparticles, as compared to other studies [27]. 
In a clinical scenario, the increased susceptibility of an implant material to 
infections is partially due to impaired host defence at the implant site which can lead to 
biomaterial-adhering biofilms or, even worst, bacteria could infect surrounding tissue, 
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where they can reside intracellularly, becoming an important source for recurrent 
biomaterial-related infections [7]. Therefore, the in vivo study was designed to 
investigate the antibacterial efficacy as well as the biocompatibility of nanoHA granules 
with and without ZnO nanoparticles. The rodent subcutaneous model is widely accepted 
as the ideal initial model for investigating the biocompatibility of bone substitutes [7, 
49, 50]. The 3 days, 1 and 4-week duration were selected because the intent was to 
assess the material during acute inflammation and after it had been largely resolved but 
before significant material degradation had occurred [49]. After 3 and 7 days 
implantation, both types of nanoHA granules activated the healing process with 
recruitment of inflammatory cells. This subsequently led to tissue formation around the 
material, particularly high density connective tissue morphology with the presence of 
fibroblasts and blood vessels [49]. Same newly formed eosinophilic connective tissues 
were also detected by Lee and collaborators in different bioceramics (HA with or 
without collagen) [35]. This rapid coverage of implant material by newly formed tissues 
may be an important additional event against bacterial infection. Concerning the 
antibacterial effect, 1 and 3-days of infection were selected once the first days after 
introducing an implant are crucial for the interactions of microorganisms with 
biomaterial and with the host immune system, which take place in the surroundings of 
the implants [51]. It is noteworthy that the in vivo biofilm prevention occurs despite the 
abundance of blood proteins that can potentially block the bactericidal action of ZnO 
nanoparticles and aid bacterial adhesion [52]. Taken together, nanoHA-ZnO porous 
granules had high antibacterial activity and did not induce any inflammation and 
toxicity in vivo. 
5. CONCLUSIONS 
Scaffold based tissue engineering has become a promising strategy in 
regenerative medicine. The experimental evidence presented herein supports the view 
that nanostructured porous granules of HA incorporated with different amounts of ZnO 
nanoparticles protect biomaterial surfaces from biofilm formation not only in vitro but 
also in vivo. Furthermore, the experimental strategy did not lead to emergence of 
resistant bacteria; it may mitigate concerns about multi-drug resistant super-bugs 
commonly seen in conjunction with approaches based on conventional antibiotics. 
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Finally, the three-dimensional and interconnected porous scaffolds supported tissue 
recovery, with the presence of new blood vessels and tissue regeneration in vivo. For 
these reasons, the porous granules of nanoHA-ZnO have the potential to improve 
numerous orthopaedic and dental applications, due to such antibacterial abilities while 
preserving biocompatibility, bioactivity and provision of adequate conditions for bone 
tissue regeneration. 
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ABSTRACT 
The high number of biomaterial associated infections demands for new strategies to 
prevent this problem. In this study the suitability of nanohydroxyapatite (nanoHA)-
based surfaces containing two Brazilian extracts of propolis (green or red ones) to 
prevent bacterial growth and biofilm formation, as well as its non-cytotoxic nature, was 
investigated. Optical density, colony forming units and MTT reduction assay were used 
to assess the materials’ antibacterial activity against planktonic and sessile growth of 
Staphylococcus aureus. NanoHA matrix was able to absorb both types of propolis and 
the obtained results revealed the antibacterial effectiveness of the novel materials 
expressed as the reduction of bacterial growth and biofilm formation ability. 
Additionally, cell culture tests showed the growth of fibroblasts with high metabolic 
activity and without membrane damage. Therefore, these nanoHA-based surfaces 
containing natural products deriving from bees may be a promising bioactive 
biomaterial to be further studied with the aim of application to orthopaedic or dental 
devices. 
 
Keywords: nanohydroxyapatite, propolis, antibacterial activity, cytocompatibility 
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1. INTRODUCTION 
The application of medical devices either for temporary or permanent use has 
become an indispensible part of regenerative medicine. However, foreign bodies are 
associated with a substantial risk of bacterial and fungal infections and, in addition, the 
alarming phenomenon of loss of efficacy of traditional antibiotic therapies urges the 
discovery of new alternatives to solve and possibly even prevent this problem. Medical 
devices could generate niches for microbial adaptation capable to favouring emerging 
pathogens previously considered saprophytic species. Moreover, once a biofilm has 
formed, it can be very difficult to treat clinically because the microorganisms inside the 
biofilm are protected from phagocytosis and antibiotics. Solutions to avoid these 
adverse events could possibly rely on tuneable biomaterials surfaces [1-3]. 
Nanosized hydroxyapatite (HA) is the main inorganic component in natural 
bone, and synthetic HA has been widely used as a biocompatible and bioactive ceramic 
in many areas of medicine, but mainly for contact with bone tissue. Due to size effects 
and surface phenomena at the nanoscale, nanophase HA possesses unique properties 
when compared to its bulk-phase counterpart. The high surface-to-volume ratio, 
reactivity, and biomimetic morphologies make nanohydroxyapatite (nanoHA) more 
favourable in applications such as dental and orthopaedic implant coatings, to stimulate 
bone growth around the implant, leading to strong bone-implant binding, or as bone 
substitute filler [4, 5]. 
Regarding orthopaedic implants, the four most prevalent bacterial species, 
accounting for over 75% of infections, are Staphylococcus aureus, Staphylococcus 
epidermidis, Pseudomonas aeruginosa and Enterococcus faecalis, while the remaining 
25% consist of a list of over 50 species, among them bacteria of the Enterobacteriaceae 
family [6]. The microbial communities associated with peri-implantitis revealed higher 
levels of Streptococcus (Streptococcus mutans and non-mutans Streptococcus), 
Butyrivibrio, Campylobacter, Peptococcus and Actinomyces [1, 7]. 
In order to eliminate or substantially reduce the extent of bacterial attachment 
and biofilm formation on biomaterials surfaces, intensive efforts have been focused on 
the development of new surfaces, or on the improvement of the performance of existing 
antibacterial surfaces [8]. 
117 
 
Due to the increasing bacterial resistance associated with chemotherapic agents, 
natural products are a promising source for the discovery of new pharmaceuticals. 
Among them, propolis (bee glue) is a natural resinous hive product produced by 
honeybees (Apis mellifera) from different plant sources. It is used by the bees to seal 
holes and cracks in their honeycombs, to smooth out the internal walls and to protect 
the colony from insect invasions and diseases [9, 10]. Propolis has been used in folk 
medicine for centuries in many regions of the world. Recently, propolis has been 
extensively used in the food industry as an additive for healthy food, beverages and 
nutritional supplements to improve health and prevent diseases. In fact, propolis 
exhibits a broad spectrum of biological properties, such as immunomodulatory, 
antitumoral, anti-inflammatory, antioxidant, and antimicrobial activities, among others 
[9, 11, 12]. The antibacterial and antifungal properties of propolis have been 
extensively investigated and, although its chemical composition is complex and linked 
to the phytogeographic origin, the activity of propolis has always been reported [13-20]. 
Under these circumstances, the aim of this work was to synthesize and 
characterize nanoHA-based surfaces containing two Brazilian ethanolic extracts of 
propolis (green and red ones). Thereafter, their antimicrobial properties, on planktonic 
and sessile growth phases of S. aureus, were evaluated as well as the materials’ 
cytocompatibility on fibroblast cells. 
 
2. MATERIAL AND METHODS 
2.1. Bacterial strain and culture conditions 
S. aureus ATCC 25923 was used in all experiments in this study. Stock cultures 
of microorganism were stored in brain heart infusion broth (BHI, HiMedia, India) 
supplemented with 20% glycerol at -80ºC. Working cultures were grown on BHI broth 
and agar (HiMedia, India) over 24 h at 37ºC. 
2.2. Ethanolic extracts of propolis 
Ethanolic extracts of red and green propolis (25%) were supplied by Pharma 
Néctar® (Belo Horizonte, Brazil). The botanic origin of red and green propolis is 
Dalbergia ecastophyllum and Baccharis dracunculifolia, respectively. 
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2.3. Synthesis of propolis containing nanoHA 
NanoHA samples were prepared as previously described [21]. Briefly, nanoHA 
powder (nanoXIM·HAp202; Fluidinova S.A., Portugal) was pressed to cylindrical 
samples and heat-treated at 830ºC, with a 10 min plateau and applying a heating rate of 
20ºC min
-1
 (Titan Platiniun 2000, EDG). For the following experiments, the samples 
were sterilized by dry heat (180ºC, 2 h). 
In order to obtain propolis containing nanoHA, first the ethanolic extracts of red 
and green propolis were diluted in a hydroalcoholic solution (50% (v/v)) to prepare the 
solutions 6, 12 and 25 µg mL
-1
. Then, the ceramic samples were immersed over-night, 
at room temperature, in these solutions. NanoHA samples were also immersed in a 
hydroalcoholic solution without propolis and were used as a control and further 
mentioned as non-treated nanoHA. After impregnation, the samples were dried at 37ºC 
for 2 h. 
2.4. Physicochemical characterization of propolis containing nanoHA 
2.4.1. Contact angle measurement 
Surface hydrophobicity was evaluated using a contact angle measurement device 
(OCA 15, DataPhysics Instruments GmbH, Germany). The sessile drop technique was 
applied with ultrapure water at room temperature. Due to the absorbing nature of 
nanoHA surfaces, the drop deposition on material surface was recorded by a video 
charge-coupled device (CCD) camera and further analyzed to obtain the contact angle 
(SCA software, DataPhysics Instruments GmbH). Values reported are the average of 
five independent measurements. 
2.4.2. Reversed-phase high performance liquid chromatography (RP-HPLC) 
Samples of nanoHA impregnated with 25 µg mL
-1
 of propolis (red or green) 
were placed into 10 mL of methanol and sonicated for 1 h to release the propolis 
compounds from the ceramic matrix. This solution was analysed by RP-HPLC with a 
liquid chromatographer. The HPLC system consisted of a JASCO PU-2080 plus ternary 
pump, a manual injector equipped with a 20 µL sample loop and a JASCO MD-2015 
plus diode array detector. A JASCO ChromPass Chromatography data system (version 
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1.8.6.1) allowed the control of the equipment and the data processing. The analytical 
column was a CC 250/4 Nucleosil 100-5 C18. The solutions were filtered with a 0.22 
µm filter (Millipore) prior to 20 µL injected into the HPLC system. The column was 
eluted by using a linear gradient of solvent water (solvent A) and methanol (solvent B), 
starting with 30% of B (0-15 min) and increasing to 90% (15-75 min), held at 90% B 
(75-95 min), and decreasing to 30% of B (95-105 min) with a solvent flow rate of 1 mL 
min
-1
. Chromatograms were recorded at 260 nm [15, 22]. The following authentic 
standards of phenolic acids and flavonoids were examined: -coumaric, ferulic acid, 
cinnamic acid, gallic acid, quercetin, hesperidin and chrysin. 
2.5. Antibacterial activity of propolis containing nanoHA 
Antibacterial activity of propolis containing nanoHA against S. aureus growth 
was determined by quantifying the planktonic bacteria held in contact with the modified 
ceramic, by OD readings and CFU counts. Therefore, 1 mL of bacterial suspension in 
BHI broth (10
6
 CFU mL
-1
) was added to each well of a 24-well plate, containing the 
material samples. After 24 h incubation at 37ºC, the OD of bacterial suspensions (total 
number of bacteria) from each well was measured at 630 nm with a microplate reader. 
In parallel, an aliquot of these suspensions, from each well, was diluted and spread on 
BHI agar plates (viable bacteria). After incubation at 37ºC for 24 h, the number of 
bacterial colonies was counted and thereafter the CFUs were calculated. Non-treated 
nanoHA was used as control. 
2.6. Biofilm formation on propolis containing nanoHA 
The propolis containing nanoHA samples were also tested to evaluate their 
potential to prevent the sessile growth of S. aureus and biofilm formation. A bacterial 
suspension was prepared and adjusted to cell density of approximately 10
6
 CFU mL
-1
 in 
BHI broth. Then, 1 mL of this bacterial suspension was inoculated onto material 
samples and after 24 h of incubation at 37ºC the bacterial suspension was removed and 
the samples were rinsed twice with 0.9% NaCl solution. Afterwards, three replicas were 
used to assess the metabolic activity of sessile bacteria by MTT assay while another 
three were used for visualization by confocal microscopy. For MTT reduction assay, 1 
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mL of 10% of (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphe-nyltetrazolium bromide dye 
(MTT, Sigma-Aldrich) (5 mg mL
-1
 in phosphate-buffered saline ) was added to each 
well, for 2 h at 37ºC. Following incubation, the MTT solution was removed from the 
wells and the material samples were transferred to new wells; 1 mL of dimethyl 
sulfoxide (DMSO, Synth, Brazil) was added for 15 min at room temperature. After 
mixing, the OD at 492 nm was measured using a microplate reader. A higher 
absorbance is related to a higher reduction of tetrazolium salt to purple formazan 
product, which indicates more viable S. aureus in the biomaterial surface. Results were 
expressed as a percentage of viable bacteria on non-treated nanoHA (0 µg ml
-1
). For 
microscopic visualization (Spectral Confocal Microscope, Leica TCS SP5), the adherent 
cells were stained using a Live/Dead® BacLight Kit (Invitrogen, USA) with SYTO 9 
and Propidium Iodide (PI), for 10 min at room temperature. The living cells appeared as 
green in colour (due to SYTO 9), while the dead cells were red (due to PI). 
2.7. Cell culture 
To access the material cytocompatibility, nanoHA impregnated with 12 µg mL
-1
 
of red or green propolis was the selected material to be tested. Non-treated nanoHA was 
used as a control. The 3T3-L1 mouse fibroblast cells were seeded on material samples 
at a density of 10
5
 cells mL
-1
 in Dulbecco’s modified Eagle’s medium (DMEM, Sigma-
Aldrich) supplemented with 10% bovine calf serum (Sigma-Aldrich) and 1% penicillin-
streptomycin (Gibco). Cell cultures were incubated at 37ºC in a humidified atmosphere 
of 5% CO2. After 1, 3 and 7 d of incubation, cell viability was evaluated through the 
MTT reduction assay and the lactate dehydrogenase (LDH) assay. 
2.7.1. Metabolic activity 
Fibroblast metabolic activity was evaluated using the MTT reduction assay. 
Briefly, after each culture time point, 10% of MTT solution (5 mg mL
-1
) was added to 
each well and the plates were incubated for 3 h at 37ºC in a humidified atmosphere of 
5% CO2. Subsequently, the MTT solution was discarded and the materials transferred to 
new wells. The formed formazan crystals were dissolved with DMSO for 15 min at 
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room temperature, followed by absorbance measurement at 550 nm on a microplate 
reader (Multiskan Spectrum, Thermo Scientific). 
2.7.2. Lactate dehydrogenase assay 
The LDH activity was detected using an assay kit (Cyto Tox 96, Promega). 
Briefly, after every culture time point, the supernatants from each individual well were 
added to a 96-well plate along with LDH assay reagent (freshly prepared) and incubated 
for 45 min. Afterwards, HCl was added to stop the reaction and the absorbance values 
were recorded at 490 nm. Results were expressed as percentage of LDH release in 
control samples (non-treated HA). 
2.8. Statistical analysis 
All experiments were conducted in triplicate. The data are reported as mean ± 
standard deviation. The differences among groups were tested by one-way analysis of 
variance (ANOVA), followed by multiple comparisons among groups using the Tukey 
HSD post hoc test (IBM
®
 SPSS
®
 Statistics, versus 19.0). In all cases, p < 0.05 was 
considered to be statistically significant. 
 
3. RESULTS 
To evaluate the propolis potential on modified nanoHA surface properties, the 
contact angle measurements were performed (table 1). The hydrophilic behaviour was 
obtained for non-treated nanoHA (0 µg mL
-1
) while, with the increase of propolis 
content on ceramic material, the surfaces exhibited increasing contact angles values, 
implying a decrease in hydrophilicity. This increase was more evident for nanoHA 
containing green propolis. 
To confirm the chemical elements of propolis released from nanoHA substrate, 
the identification of flavonoid and other phenolic constituents was carried out by direct 
HPLC comparison with authentic standards and was based on retention time, co-
chromatography, and the identity of absorption spectra. The results are shown in table 2. 
Both materials released coumaric acid, ferulic acid, hesperidin and quercetin. However, 
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cinnamic acid and chrysin were only detected for nanoHA-RP. Gallic acid was not 
detected for either of the materials. 
Table 1. Contact angle values of nanoHA samples impregnated with different 
concentrations of red (RP) and green propolis (GP) solutions. 
 
Contact angle (º) 
nanoHA-RP nanoHA-GP 
0 µg mL
-1
 12.38 ± 1.15 12.38 ± 1.15 
6 µg mL
-1
 15.78 ± 2.62 32.66 ± 5.81
a
 
12 µg mL
-1
 19.69 ± 2.31 49.87 ± 2.89
a
 
25 µg mL
-1
 40.80 ± 6.97
a
 65.28 ± 6.13
a
 
ap  0.05, compared to non-treated nanoHA (0 µg mL-1) 
Table 2. Phenolic acids and flavonoids released from nanoHA matrix 
impregnated with 25 µg mL
-1
 of red (RP) and green propolis (GP), detected by 
RP-HPLC (RT: retention time, min). 
Compound 
RT (min) 
nanoHA-RP nanoHA-GP 
Gallic acid nd nd 
Ferulic acid 2.37 2.37 
-Coumaric acid 2.52 2.53 
Cinnamic acid 3.67 nd 
Hesperidin 22.19 22.13 
Quercetin 40.67 40.77 
Chrysin 54.35 nd 
nd: not detected 
The effect of propolis containing nanoHA materials on the planktonic and sessile 
growth phases of S. aureus, after a 24 h period of exposure, is shown in figures (1-3). 
With regard to the planktonic bacteria, two methodologies, OD readings and CFU 
counts, were applied to evaluate the materials’ bacteriostatic or bactericidal effect. In 
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comparison with non-treated nanoHA, all nanoHA samples containing either red or 
green propolis exhibited a significant reduction in the total number of bacteria as well as 
in the number of viable bacteria (figure 1). The nanoHA impregnated with the two 
highest concentrations of red propolis showed a remarkable reduction of 99% in the 
number of viable bacteria (figure 1(a)), while nanoHA with green propolis for the same 
concentrations showed a reduction of 45 and 61%, respectively (figure 1(b)). The effect 
of propolis on S. aureus cells appears to be a bactericidal one, with the red propolis 
having a stronger antibacterial activity in comparison to the green one. 
 
Figure 1. Planktonic growth of S. aureus, evaluated in terms of total cells (OD) and 
viable cells (CFU mL
-1
), after 24 h incubation with nanoHA samples impregnated with 
different concentrations of red (a) and green (b) propolis solutions. 
*
p  0.05, significant 
reduction compared to non-treated nanoHA (0 µg mL
-1
). 
 
Figure 2. Sessile growth of S. aureus on nanoHA samples impregnated with different 
concentrations of red (RP) and green propolis (GP) solutions, as a percentage of viable 
bacteria on non-treated nanoHA (0 µg mL
-1
), determined by MTT reduction assay, after 
24 h of incubation. 
*
p  0.05, significant reduction compared to non-treated nanoHA (0 
µg mL
-1
). 
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In order to investigate the effect of the propolis containing nanoHA samples on 
S. aureus biofilm formation, the metabolic activity of the bacterial cells attached on the 
material surface was evaluated by MTT reduction assay and further assessed by 
confocal microscopy using a Live/Dead staining. The results obtained showed a general 
reduction of S. aureus activity in a concentration-dependent way which was significant 
at just 6 µg mL
-1
 for both tested propolis types, as depicted in figure 2. Moreover, the 
nanoHA impregnated with the highest concentration of red propolis solution was able to 
inhibit 80% of the staphylococcal biofilm. Lastly, the ability of propolis containing 
nanoHA to prevent bacterial sessile growth was confirmed by fluorescence microscopy 
(figure 3). After 24 h of culture, a high number of viable S. aureus on pure nanoHA 
samples was observed. Comparatively, propolis containing nanoHA exhibited an overall 
decrease of bacterial density in a concentration-dependent way, followed by an increase 
in dead cells.  
 
Figure 3. Fluorescence images showing the viability of S. aureus on nanoHA samples 
impregnated with different concentrations of red (RP) and green propolis (GP) 
solutions. The living bacteria are coloured green, while the dead ones are coloured red. 
Scale bar 50 µm. 
In general, all nanoHA samples impregnated with red or green propolis affected 
the growth of planktonic cells as well as sessile bacteria in a similar way. 
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The potential application of nanoHA supplemented with red or green propolis in 
biomedical devices has been evaluated. For that purpose, the material cytocompatibility 
was analyzed using fibroblastic cell cultures, by MTT reduction assay and LDH release, 
after 1, 3 and 7 d of culture. NanoHA impregnated with a solution of 12 µg mL
-1
 of red 
or green propolis was selected once it was at the concentration that proved able to 
promote a reduction of around 50% in the number of sessile bacteria on material 
surface. For nanoHA with red propolis, for all time points, a high metabolic activity of 
fibroblast cells was observed, as indicated by the increase in MTT reduction, and 
comparatively to non-treated nanoHA (figure 4). Similar results were obtained for 
nanoHA with green propolis, except for day 1, where a fraction of just 57% remained 
active. Nevertheless, at day 3 and 7, the metabolic activity reached similar values to 
those of non-treated nanoHA. Material cytotoxicity was evaluated by LDH assay. LDH 
is a stable cytosolic enzyme released upon membrane damage in necrotic cells [23]. The 
analysis of LDH release levels at different time points in the culture medium did not 
reveal significant changes between cells cultured on treated and non-treated nanoHA, as 
depicted in figure 5. This means that the materials induced no, or only marginal, 
cytotoxicity on fibroblastic cells. 
 
Figure 4. Metabolic activity of fibroblast cells cultured on nanoHA impregnated with 
red (RP) and green propolis (GP) for 1, 3 and 7 d, estimated by MTT assay. Non-treated 
nanoHA was considered 100% of cell viability. 
*
p  0.05, compared to non-treated 
nanoHA (0 µg mL
-1
). 
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Figure 5. Cytotoxicity of nanoHA impregnated with red (RP) and green propolis (GP) 
to fibroblast cells, after 1, 3 and 7 d of culture, evaluated by LDH assay. Results were 
expressed as a percentage of LDH release in control samples (non-treated HA). 
 
4. DISCUSSION 
Propolis comprises a broad spectrum of biological properties and, as a result, it 
has been explored as a novel agent for biomedical applications [24-28]. Nevertheless, 
the use of propolis containing nanoHA as a bioactive biomaterial, which is useful in 
orthopaedics or dental applications to stimulate bone growth and to prevent biomaterial-
associated infections, has never been tested. Therefore, the present study evaluates the 
effect of these new materials based on nanoHA impregnated with propolis extracts on S. 
aureus growth, a major pathogen related to implanted medical devices [1, 6], as well as 
on the cytocompatibility with fibroblastic cells. Ethanolic extracts of two distinct types 
of propolis were used, namely Brazilian red propolis derived mainly from the surface of 
D. ecastophyllum, located in mangrove areas in the north-eastern Brazil [29, 30]; and 
Brazilian green propolis or alecrim propolis whose botanical origin is mainly B. 
dracunculifolia exudates, the dominant source of propolis in south-eastern Brazil [22, 
31]. 
The nanoHA-based surfaces containing red or green propolis exhibited a 
significant inhibition of S. aureus planktonic and sessile growth (figures 1 and 2). 
Wherein, the nanoHA containing red propolis displayed a higher antibacterial activity 
when compared to the absorbing green counterpart, as was also confirmed by confocal 
microscopy (figure 3). A large number of constituents have been identified in Brazilian 
propolis samples and the antibacterial activity has been mainly attributed to phenolic 
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compounds, especially flavonoids, phenolic acids and esters [32-34]. However, the 
higher antibacterial activity expressed by red propolis may be attributed to the 
difference in its chemical composition and concentration of components which derives 
mainly from isoflavones (daidzein, formononetin and biochanin A), and its total 
phenolic compounds content which is higher than any ever found on other Brazilian 
propolis and which seems to contribute to higher antibacterial effect [19, 29, 35, 36]. In 
contrast, the antibacterial activity of green propolis derives mainly of flavonoids, 
aromatic acids, and esters present in resins, galangin, kaempferol, pinostrobin, and 
pinocembrin which are known to be more effective agents against bacteria. Ferulic acid 
and caffeic acid also contribute to the bactericidal action of propolis [12, 32, 37]. 
Salomão et al [20] found a positive correlation between the -coumaric acid amount in 
propolis and the bactericidal effect on S. aureus. Some of these compounds were 
identified in the present work by RP-HPLC analysis (table 2), including -coumaric 
acid. Nevertheless, the observed differences in the chemical profile could provide an 
explanation for the differences found in the antibacterial activities of the distinctive 
types of propolis. Moreover, the compound’s concentration may also dictate the 
observed effects. Cinnamic acid and chrysin are typical constituents of propolis. Their 
absence in the solution from green propolis containing nanoHA may be related to their 
presence below the detection limits [22]. Additionally, propolis compound’s affinity to 
nanoHA substrate may have dictated the chemical and antibacterial profiles. As 
highlighted by the contact angle measurements (table 1), an increase in such values was 
observed which is related to the lipophilic nature of propolis [12, 38]. However, this 
increase was not as high for nanoHA containing red propolis which may be due to its 
chemical profile consisting of substances of a more polar nature [36], that in turn may 
have a higher affinity for the hydrophilic nanoHA substrate [21]. The higher 
antibacterial activity against planktonic growth may be attributed to the diffusion of 
active constituents of propolis towards the ceramic matrix. 
As described, the composition of propolis is very complex and its antibacterial 
activity is linked to some of the above mentioned constituents or to the synergistic 
action of several such components. Some mechanisms of propolis activity on the 
bacterial growth have been reported, such as inhibition of protein synthesis or functional 
and structural damage on the bacterial cell membranes and cell walls [39, 40]. Propolis 
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phenolics are generally linked to destabilization and permeabilization of the 
cytoplasmatic membrane, protein denaturation or inhibition of extracellular enzymes 
[41, 42]. Galangin, caffeic and cinnamic acids are enzymatic inhibitors responsible for 
blocking bacterial growth and proliferation. Other flavonoids, such as quercetin, affect 
bacterial membrane potential, causing increased membrane permeability, and inhibit 
bacterial motility [43-45]. It is clear that the mechanism of propolis activity on bacterial 
cells is complex and a simple analogy cannot be established with the mode of action of 
any classic antibiotics. Interestingly enough, synergy between propolis and a range of 
antibiotics has been shown against some bacteria, and when using a mixture of both 
products the effective dose of antibiotics was reduced [40, 43, 46-48]. 
In addition, propolis may also suppress microbial virulence factors. Scazzocchio 
et al [46] demonstrated a multiple action of propolis against different virulence factors 
of some Gram-positive bacteria of clinical interest. Staphylococcus’s virulence factor 
coagulase was completely suppressed by propolis as lipase, and a dose-dependent 
prevention of biofilm formation was reported. Mirzoeva et al [43] found that the anti-
motility action of propolis components may play an important role in inhibition of 
bacterial pathogenesis and the development of infection once bacterial motility is 
important in virulence, as it guides bacteria to their sites of adherence and invasion. 
Besides their antibacterial activity, the results obtained with fibroblasts cultures 
are noteworthy as they revealed that nanoHA impregnated with propolis was non-
cytotoxic. Instead, nanoHA impregnated with red propolis led to an increase in cell 
metabolic activity in comparison with non-treated nanoHA (figure 4). The LDH assay 
also confirmed these results once that similar profiles of LDH release were observed for 
treated and non-treated nanoHA (figure 5). These results are in agreement with other 
studies, using fibroblasts or other cell types [23, 45, 49, 50]. Al-Shaher et al. [51] 
reported that propolis exerts minimal toxicity on both fibroblasts of the periodontal 
ligament (PDL) and dental pulp at concentrations of 4 mg mL
-1
 or lower. Likewise, 
Gjertsen et al. [52] observed that propolis not only decreased apoptosis but also 
increased the metabolic activity and proliferation of PDL cells. 
Our data, together with the widespread appearance of antibiotic resistance and 
propolis large broad-spectrum antimicrobial activity and its lower risk for the 
development of resistance, may indicate that propolis can be, by itself, a bioactive 
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product, or be a promising source of new bioactive compounds to prevent and treat 
biomaterial-associated infections. 
 
5. CONCLUSION 
The potential pharmacological activity of natural products, especially 
antimicrobial activity, has attracted the attention of several researchers. The results 
obtained in this work indicated that propolis containing nanoHA was able to hinder the 
bacterial growth and biofilm formation of S. aureus, as well as be non-cytotoxic to 
fibroblast cells. These findings encourage the future studies of these materials in terms 
of application to dental and orthopaedic implant coatings, to stimulate bone growth 
around the implant, and to prevent implant associated infections. 
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ABSTRACT 
Candida can adhere and form biofilms on biomaterials commonly used in medical 
devices and is a key attribute that enhances its ability to cause infections in humans. 
Furthermore, biomaterial-related infections represent a major therapeutic challenge 
since Candida biofilms present considerable resistance to most conventional antifungal 
therapies. As a result, there is a strong medical but also economical motivation for the 
development of newer and more potent antifungal agents. In the present work, the 
activity of three novel imidazole derivatives, 5-aminoimidazole-4-carboxamidrazones, 
namely 2h, 2k and 2l, to prevent Candida albicans and Candida krusei biofilm 
formation, as well as to eradicate pre-formed Candida spp biofilms on 
nanohydroxyapatite (nanoHA) substrates were investigated. To address these goals, 
both quantitative methods by cultivable cell numbers and qualitative evaluation by 
scanning electron microscopy were used. Compounds cytocompatibility towards 
osteoblast-like cells was also evaluated after 24 h and 48 h of exposure, through 
resazurin assay. The three tested antifungal agents displayed strong inhibitory effect on 
biofilm development by both Candida species as potent in vitro activity against sessile 
C. albicans cells. Additionally, morphological changes following treatment with the 
imidazole derivatives were observed by SEM on nanoHA surfaces for both Candida 
species. Regarding cytocompatibility, a time- and concentration-dependent effect was 
observed. Together these findings indicated that the potent activity of 5-
aminoimidazole-4-carboxamidrazones derivatives on Candida spp biofilms, in 
particular 2l compound, is worth further investigating, aiming at developing preventive 
approaches to fight biofilm-associated infections involving biomaterials. 
 
Keywords: 5-aminoimidazole-4-carboxamidrazones, Candida biofilm, 
nanohydroxyapatite, cytocompatibility 
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1. INTRODUCTION 
Yeast cells have the ability to adhere and colonize surfaces of a wide range of 
synthetic materials of polymeric, ceramic, and metallic compositions, often used in 
medical devices, in almost the same manner as to host mucosal surfaces [1-4]. In 
particular, Candida species are commensal microorganisms that colonize skin and 
mucosal surfaces in healthy humans thus facilitating their contact with most implanted 
biomaterials [5, 6]. Accordingly, the increase in fungal infections in the last decades has 
almost paralleled the increase and widespread use of a broad range of indwelling 
medical devices, mainly in populations with impaired host defences [5]. Although these 
infections are considered rare, little is known about their prevalence, the accuracy of the 
currently used diagnostic protocols, or the most effective treatment. As a result, they 
pose a serious health problem in the future. The vast majority of those infections is 
caused by Candida species. Particularly C. albicans shows the highest virulence among 
all the currently known medically relevant species of Candida and is the most common 
fungal species associated with biofilm formation in the clinical setting [7-9]. 
Nonetheless, other non-albicans species as Candida glabrata, Candida parapsilosis, 
Candida krusei and Candida tropicalis have been implicated in biofilm-related 
infections and are increasingly recognized as nosocomial pathogens of clinical interest 
[5, 9-11]. The most important virulence trait for numerous Candida species in the 
pathogenesis of device-related infections is the formation and establishment of 
proliferating biofilms [5, 12]. These are well structured microbial communities where 
the cells bind tightly to a surface and become embedded within a protective self-
produced extracellular polymeric matrix [5]. The cellular communities formed on 
biomaterial surface have a characteristic architecture and phenotypic features that are 
distinct from their planktonic, free-floating counterparts [2, 13, 14]. Mature C. albicans 
biofilms have a complex three-dimensional architecture with wide spatial heterogeneity, 
consisting of a mixture of morphological forms namely yeast, pseudohyphae and 
hyphae, encased within a matrix of polysaccharides, carbohydrates and proteins [15, 
16]. It has been shown that C. albicans produces larger and more complex biofilms than 
other Candida species [17]. Candida colonization of medical devices not only precedes 
infection, but it can also adversely affect the performance of the implanted medical 
device [5]. Once Candida biofilms are formed in vivo, removal of the substrate that is 
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supporting the biofilm growth, together with long term antifungal therapy 
administration, are almost always required to control the infection and to avoid 
potentially fatal consequences, since yeast detachment from biofilm can cause an acute 
fungemia and/or life-threatening systemic infections [2, 12, 18]. Unfortunately, often 
removal is impossible, due to the patient’s condition, the anatomic location, or 
underlying disease. From the clinical perspective, the most important features of 
Candida biofilms are their ability to withstand host defence mechanisms and their 
increased resistance to conventional antifungal agents, often resulting in serious and 
persistent infections [1, 13]. Together with the emergence of Candida species resistant 
to azole drugs [10, 19], there is a continuous need for the development of newer and 
more potent antifungal agents that are also effective against Candida biofilm infections. 
In a previous work, the synthesis and antifungal activity of a series of novel 5-
aminoimidazole-4-carboxamidrazones were reported by our group [20]. These new 
imidazole derivatives exhibited promising antifungal activity and three of them, (Z)-5-
amino-N'-aryl-1-methyl-1H-imidazole-4-carbohydrazonamides 1 [aryl=phenyl (2h), 4-
fluorophenyl (2k), 3-fluorophenyl (2l)], have proven to be very effective against 
different clinically important yeasts, such as C. albicans, C. krusei, C. parapsilosis and 
Cryptococcus neoformans [20]. In this context, the aims of this study were: (i) to 
evaluate the effectiveness of these three novel antifungal agents to impair C. albicans 
and C. krusei biofilm formation on nanohydroxyapatite substrates, which is a well-
known biocompatible and bioactive calcium phosphate ceramic material; (ii) to 
determine the compounds interference with a pre-formed Candida spp biofilm; and (iii) 
to assess the compounds cytocompatibility towards osteoblast-like cells (MG-63 cell 
line). 
 
2. MATERIALS AND METHODS 
2.1. Preparation of nanohydroxyapatite samples 
Nanohydroxyapatite (nanoHA; nanoXIM·HAp202; Fluidinova S.A.) powders, 
uniaxially pressed as cylindrical disc samples, were sintered at 830ºC during 15 min 
using a heating rate of 20ºC/min, as described elsewhere [21, 22]. Prior to biological 
experiments, the biomaterials were sterilized by dry heat (180ºC, 2 h). 
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2.2. Antifungal agents 
The stock solutions of 5-aminoimidazole-4-carboxamidrazones derivatives, 
namely 2h, 2k and 2l, were prepared as described elsewhere [20] and were freshly 
solubilised in dimethyl sulfoxide (DMSO, Applichem) at 10 mg/mL. Subsequent 
dilutions were made in yeast nitrogen base (YNB, Fluka) supplemented with glucose to 
obtain the desired concentrations, just prior the assays. 
2.3. Candida strains and growth conditions 
Candida albicans and Candida krusei reference ATCC strains 10231 and 6258, 
respectively, were subcultured and grown in Sabouraud dextrose agar plates (SDA, 
Liofilchem) at 37ºC for 24 h. After cultured, cells were harvested and diluted to the 
desired concentrations with glucose supplemented YNB medium. 
2.4. Effect of 5-aminoimidazole-4-carboxamidrazones derivatives on 
Candida spp biofilm formation 
The compounds potential to prevent biofilm formation of C. albicans and C. 
krusei on nanoHA surface was evaluated using an adapted method described by [23]. 
Briefly, 50 μL of yeast suspension in YNB medium (final concentration of 5×102 or 
1×10
6
 cells/mL) were added to equal volume of compounds solutions (1:2 dilutions) 
into the wells of a flat bottom 96-well plate, containing the nanoHA discs. The yeast 
cells were allowed to adhere on discs surface for 24 h at 37ºC with moderate shaking. 
Discs of nanoHA incubated with yeast suspension and YNB medium were used as 
control (drug-free). After incubation the medium was removed and the biomaterials 
were gently rinsed twice with saline solution (0.9% NaCl, JT Baker) to remove non-
adherent cells. The anti-biofilm effect was determined by colony-forming units (CFU) 
and scanning electron microscopy (SEM), as described below. 
2.5. Effect of 5-aminoimidazole-4-carboxamidrazones derivatives on pre-
formed Candida spp biofilm 
The ability of imidazole derivatives to eradicate established C. albicans and C. 
krusei biofilms were assessed using an adapted method described herein [24]. Briefly, 
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100 μL of standardized yeast suspension in YNB medium (final concentration of 5×102 
or 1×10
6
 cells/mL) were added into the wells of a flat bottom 96-well plate, containing 
the nanoHA discs. The plates were kept at 37ºC for 24 h, with moderate shaking, to 
allow biofilm formation on nanoHA surface. After incubation, the medium was 
discarded and each biomaterial sample harbouring biofilm was rinsed once with saline 
solution to eliminate non-adherent cells. With sterile forceps the nanoHA discs were 
transferred to a new microtitre plate. The compounds (100 μL per well), at different 
concentrations, were added into the wells and the plates were incubated for an 
additional 24 h period at 37ºC, under moderate shaking. As control, Candida cells were 
incubated with YNB medium (drug-free). Following incubation, the medium was 
removed and the biomaterials were gently rinsed twice with saline solution. The 
antifungal effect of 5-aminoimidazole-4-carboxamidrazones derivatives against sessile 
cells was assessed by CFU and SEM, as described below. 
2.6. Candida viability assay 
The number of cultivable yeast cells, adhered on biomaterial surface, was 
determined by CFU enumeration. Briefly, nanoHA discs were transferred to an 
Eppendorf containing 1 mL of saline solution and were sonicated for 5 min in an 
ultrasonic bath (35 kHz, Bandelin-RK 156). The solutions containing the dispersed cells 
were then appropriately diluted and spread on SDA plates. After inoculation, the plates 
were incubated at 37ºC for 24 h. The number of colonies were counted and expressed as 
CFU/mm
2
. 
2.7. Scanning electron microscopy 
The morphological effect of 5-aminoimidazole-4-carboxamidrazones on C. 
albicans and C. krusei cells was observed by SEM. Initially, the cells on nanoHA 
surface were fixed with 3% (v/v) glutaraldehyde solution in cacodylate buffer (Sigma-
Aldrich) for 30 min at room temperature. Subsequently, the samples were dehydrated in 
a series of ethanol-water solutions followed by a series of hexamethyldisilazane 
(HMDS, Sigma-Aldrich)-ethanol solutions with concentrations ranging between 50% 
and 100%, for 10 min each, and finally air dried overnight. The samples were attached 
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on aluminium stubs with carbon tape, sputter-coated (SPI-Module) with a thin 
conductive film of Au-Pd alloy and then imaged by SEM using a FEI Quanta 400 
FEG/ESEM microscope, under 500x and 5000x magnification in high-vacuum mode, at 
15 kV accelerating voltage. 
2.8. Cytocompatibility of 5-aminoimidazole-4-carboxamidrazones 
derivatives 
Osteoblast-like cells (MG-63 cell line) were cultured in alpha minimum essential 
medium (α-MEM, Sigma-Aldrich) supplemented with 10% (v/v) heat-inactivated fetal 
bovine serum (FBS, Gibco), 1% (v/v) penicillin-streptomycin (100 IU/mL penicillin 
and 2.5 µg/mL streptomycin, Gibco), and 1% amphotericin B (2.5 µg/mL, Gibco), at 
37ºC, in a humidified atmosphere of 5% CO2 and 95% air. The compounds solutions 
were diluted in supplemented -MEM to appropriate concentrations that comprised all 
values previously assessed. Similarly to what was done for the microbiological studies, 
two approaches were tested: (a) 50 μL cell suspension (final concentration 104 cells/mL) 
was simultaneously seeded with equal volume of freshly prepared compounds solution, 
into 96-well plates containing the nanoHA discs. The plates were then incubated for 24 
and 48 h; (b) cells (100 μL per well at 104 cells/mL) were allowed to attach on nanoHA 
surface for 24 h prior exposure to freshly prepared compounds dilutions (100 μL per 
well) for additional 24 and 48 h incubation time. For both approaches, compounds-free 
culture medium was used as a negative control. After the incubation periods, the cellular 
metabolic activity was determined by rezasurin assay. Thus, cells were incubated with 
resazurin solution (0.1 mg/mL, Sigma-Aldrich) for 3 hours at 37ºC. Afterwards, the 
supernatant had the fluorescence intensity measured in a fluorimeter (excitation: 530 nm 
and emission: 590 nm, Synergy HT, BioTek). 
2.9. Statistical analysis 
Each condition was tested in triplicate and two independent experiments were 
performed. The experimental data were expressed as the mean ± standard deviation and 
analyzed using IBM® SPSS® Statistics (vs. 20.0, SPSS, USA). One-way analysis of 
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variance (ANOVA) followed by the post hoc Tukey HSD multiple comparison test, 
which was used to denote the significance level (p < 0.05). 
 
3. RESULTS 
3.1. Ability of 5-aminoimidazole-4-carboxamidrazones derivatives to 
prevent Candida spp biofilm formation 
Figure 1. In vitro effect of 5-aminoimidazole-4-carboxamidrazones derivatives against 
C. albicans and C. krusei biofilm growth on nanoHA surface. Yeast cells were allowed 
to adhere in the presence of different concentrations of antifungal agents and after 24 h 
incubation the number of cultivable yeast cells was determined by CFU enumeration 
(CFU/mm
2
). (*) indicates significant difference between antifungal treatment and the 
control (drug-free) (p  0.05). 
Based on a previous work by Ribeiro et al [20] where the minimal inhibitory 
concentration (MIC) of 2h, 2k and 2l compounds was determined against C. albicans 
and C. Krusei, the concentrations tested in the current study were thereafter established 
and they are the MIC, 2-fold superior or 2-fold inferior to MIC, for each Candida 
species. 
Initially, yeast cells were allowed to adhere to nanoHA surface in the presence 
of antifungal agents and the effect of these different concentrations on biofilm growth of 
C. albicans and C. Krusei were assessed using two distinct initial inoculums. For an 
initial inoculum of 10
6
 CFU/mL, the three imidazole derivatives were able to 
significantly inhibit the adhesion of both Candida species, for all tested concentrations, 
compared to that on drug-free (control) biomaterials (Fig. 1). In particular, the two 
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highest concentrations tested showed a reduction higher than 80% for both Candida 
species. As foreseen, using a lower inoculum (5×10
2
 CFU/mL), the three antifungal 
agents enabled a total inhibition of C. albicans and C. krusei adhesion on nanoHA 
surface, for the tested concentrations (data not shown). 
3.2. Effect of 5-aminoimidazole-4-carboxamidrazones derivatives on pre-
formed Candida spp biofilm 
Figure 2. Number of remaining viable cells on nanoHA surface after treatment of 24 h-
biofilm of C. albicans and C. krusei with different concentrations of 5-aminoimidazole-
4-carboxamidrazones derivatives, expressed as CFU/mm
2
. Initial yeast inoculum of 
5×10
2
 CFU/mL. *p  0.05, differences statistically significant compared to control 
(drug-free). 
Figure 3. Number of remaining viable cells on nanoHA surface after treatment of 24 h-
biofilm of C. albicans and C. krusei with different concentrations of 5-aminoimidazole-
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4-carboxamidrazones derivatives, expressed as CFU/mm
2
. Initial yeast inoculum of 10
6
 
CFU/mL. *p  0.05, differences statistically significant compared to control (drug-free). 
To explore the efficacy of imidazole derivatives in developing biofilms, C. 
albicans and C. krusei were cultured, at two different initial inoculums, for 24 h on 
nanoHA discs to allow yeast cells attachment. The pre-formed biofilms were then 
exposed to the antifungal agents and after 24 h, the number of viable adherent cells was 
quantified by cultivable cell number assay (Figs. 2 and 3). As depicted in Figure 2, 
using an initial inoculum of 5×10
2
 CFU/mL, a significant reduction ( 90%) in the 
number of remaining viable C. albicans cells was achieved, when compared to non-
treated (drug-free) biofilms, for all assessed conditions. Regarding C. krusei, 2l 
compound exhibited a sharp reduction of 88% for concentration as low as 1.6 µg/mL, 
whereas for 2h and 2k compounds a concentration-dependent effect was observed. 
Nevertheless, for the three tested concentrations a significant reduction in C. krusei 
sessile cell number was observed. 
A second set of experiments was performed with a higher initial inoculum (10
6
 
CFU/mL) (Fig. 3) and despite this increase, the three imidazole derivatives displayed 
similar effect for the two highest concentrations against C. albicans sessile population 
when compared to the previously indicated results (Fig. 2). On the other hand, for C. 
krusei a concentration-dependent effect was noticed. Even so, the observed reduction 
never reached values higher than 61%, 38% and 70% for the highest concentration 
tested of 2h, 2k and 2l compounds, respectively (Fig. 3). 
3.3. Direct visualization of 5-aminoimidazole-4-carboxamidrazones 
derivatives effect on Candida spp biofilm 
SEM analysis, as exemplified in Figure 4, had shown a reduction in the number 
of adherent cells on nanoHA surface for both Candida species, after incubation with the 
three components tested, either for biofilm prevention or biofilm elimination 
experimental approaches. Additionally, C. albicans exhibited a highly heterogeneous 
structure, with morphological switch between yeast, pseudohyphae and hyphae, after 
exposure to the compounds, more evident for 2h compound, while on drug-free samples 
a predominately yeast morphology was observed (Figs. 4 and 5). Higher magnification 
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images also enabled the visualization of round or oval blastospores (yeast forms) 
aggregated either in pairs or clumps for both Candida species with some budding yeasts 
(Figs. 5 and 6). However, while C. albicans structures had a full shape and smooth 
surface (Fig. 5), some C. krusei cells treated with 5-aminoimidazole-4-
carboxamidrazones derivatives appeared shrunk, wrinkled and disc-like depressions, 
with different depths, were present at the cell surface, as indicated in Figure 6. 
 
Figure 4. Morphology and spatial distribution of C. albicans cells on nanoHA surface 
after 24 h incubation with 5-aminoimidazole-4-carboxamidrazones derivatives under 
SEM visualization. (A) control (drug-free); (B) 2h; (C) 2k and (D) 2l compounds at 0.0; 
25.0; 25.0 and 12.5 µg/mL, respectively. Magnification 500x. Scale bar 100 µm. 
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Figure 5. Morphology of C. albicans cells on nanoHA surface after 24 h incubation 
with 5-aminoimidazole-4-carboxamidrazones derivatives under SEM visualization. (A) 
control (drug-free); (B) 2h; (C) 2k and (D) 2l compounds at 0.0; 25.0; 25.0 and 12.5 
µg/mL, respectively. Magnification 5000x. Scale bar 10 µm. 
 
Figure 6. Morphology of C. krusei cells on nanoHA surface after 24 h incubation with 
5-aminoimidazole-4-carboxamidrazones derivatives under SEM visualization. (A) 
control (drug-free); (B) 2h; (C) 2k and (D) 2l compounds at 0.0; 3.1; 3.1 and 1.6 µg/mL, 
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respectively. Arrows indicate the presence of disc-like depressions in cell surface. 
Magnification 5000 x. Scale bar 10 µm. 
3.4. Cytocompatibility of 5-aminoimidazole-4-carboxamidrazones 
derivatives 
MG-63 cells were exposed to different concentrations of imidazol derivatives 
that comprised all values assessed in the microbiological studies. A preliminary study 
had shown that the lower and the higher concentration of each compound exhibited no 
cytotoxicity and high cytotoxicity, respectively. For that reason, such values were 
excluded from the subsequent tests. Similarly to microbiological studies, two different 
approaches were tested. In a first approach, mammalian cells were simultaneously 
incubated with the compounds and the cellular metabolic activity was assessed after 24 
h and 48 h of exposure (Fig. 7). Similar results were obtained for 2h and 2k compounds 
where 6.3 µg/mL had no cytotoxic effect after both incubation time points. However, 
for the subsequent concentrations, a concentration- and time-dependent effect was 
observed. The two highest concentrations of 2h compound, namely 25.0 and 50.0 
µg/mL, proved to be highly cytotoxic. On the other hand, 2l compound presented the 
best cytocompatibility results, except for 25 µg/mL. Even though a time-dependent 
effect was noticed, the viability remained above 70% when compared to control (drug-
free). Regarding the second set of experiments, the cells were allowed to adhere on 
nanoHA surface and, thereafter exposure to the compounds during 24 and 48 h. As 
depicted in figure 8, the obtained results are rather similar to the previous assay, mainly 
for 2k and 2l compounds. For 2h compound a sharp reduction on cellular metabolic 
activity after 48 h of exposure is noticed, for the lowest concentrations (6.3 and 12.5 
µg/mL). 
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Figure 7. Effect of 5-aminoimidazole-4-carboxamidrazones derivatives on MG-63 cells 
metabolic activity. Cells were incubated simultaneously with different concentrations of 
the compounds on nanoHA surface for 24 h and 48 h. After incubation, cell viability 
was determined using resazurin assay. *p  0.05, differences statistically significant as 
compared with control (drug-free samples, 0 µg/mL). 
 
Figure 8. Effect of 5-aminoimidazole-4-carboxamidrazones derivatives on MG-63 cells 
metabolic activity. Cells were allowed to adhere on nanoHA substrate for 24 h and were 
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then treated with different concentrations of the compounds for 24 h and 48 h. After 
incubation, cell viability was determined using resazurin assay. *p  0.05, differences 
statistically significant as compared with control (drug-free samples, 0 µg/mL). 
 
4. DISCUSSION 
In the present study the ability of three novel 5-aminoimidazole-4-
carboxamidrazones derivatives to prevent or eliminate C. albicans and C. krusei 
biofilms is addressed for the first time. Both Candida species are causative agents of 
device-related infections [5, 12]. C. krusei, although less prevalent than C. albicans, has 
emerged as an important pathogenic, especially due to its great capacity to form biofilm 
[6, 11] and intrinsic resistance to fluconazole combined with reports of decreased 
susceptibility to both flucytosine and amphotericin B [25, 26]. Whereas the rate of 
successful treatment of oropharyngeal and esophageal candidiasis remains high, device-
related infections by Candida species may represent a diagnostic and a therapeutic 
challenge. Even with antifungal agents currently in clinical use mortality of patients 
with invasive candidiasis, usually associated with indwelling medical devices, can be as 
high as 40% [7, 16]. Systemic administration of antifungal agents, mainly amphotericin 
B and fluconazole, is the ‘gold standard’ for the treatment of these infections, however 
drug therapy alone will only suppress clinical symptoms of infection at the expense of 
potential toxic side effects [8, 18]. One major reason for this low success rate is related 
with pathogenic biofilms formed on the implant surface and there appear to be multiple 
resistance mechanisms [4, 5, 14, 27]. Candida species are able to attach and form 
biofilm on virtually any implanted medical device in the human host, from synthetic 
polymers like silicone elastomer, polystyrene, polyvinyl chloride, polyurethane, to 
acrylic and metallic surfaces, among others [17, 28-33]. Biofilm formation studies on 
clinically used ceramics are yet not so abundant. Accordingly, the chosen substrate was 
nanoHA since is a frequently applied ceramic material for coating metallic implants or 
filling small bone defects in orthopaedics and dentistry, due to its high biocompatibility 
and bioactivity [34]. Sessile cells that are encountered in many biofilm-based device-
related infections are highly resistant to the most commonly used antifungal drugs 
including fluconazole, caspofungin, nystatin, amphotericin B, and chlorhexidine [17, 
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24, 30, 35, 36]. For instance, C. albicans biofilms are up to 4000 times more resistant to 
fluconazole than their planktonic counterparts [5]. 
The earliest stage in Candida infection is the cellular attachment onto implant 
surfaces, often leading to biofilm development, resulting from the presence of a slimy 
extracellular matrix, strongly binding the cells between themselves and to the substrates. 
Preventing this early step is therefore critical to achieve efficient and cost-effective 
struggle against implanted medical devices infections. In the first part of this study, the 
compounds ability to restrain C. albicans and C. krusei biofilm formation, through 
simultaneous incubation of yeast cells and the compounds on nanoHA substrate, was 
evaluated. The three compounds were highly efficient in preventing Candida spp 
adhesion at concentrations equal or lower than their MICs. However, in clinical settings 
it’s often required to act against pre-formed biofilms on implant surfaces. Consequently, 
in the second part of this study, the compounds effect on pre-formed Candida spp 
biofilm was evaluated. The tested compounds showed to be very effective against C. 
albicans, mostly 2k and 2l compounds. Regarding C. krusei, such effect against sessile 
population was not as strong as for C. albicans. For instance, the compounds exhibited 
low inhibition when a higher initial inoculum concentration was used. The results 
clearly indicate that the observed effect depends on the initial number of cells, as well as 
on the used species, which is consisting with other reports. Perumal et al [37], in a 
series of experiments, studied the contribution of cell density towards antifungal drug 
resistance in C. albicans biofilms and concluded that azole drug tolerance at high cell 
density differed mechanistically from tolerance at low cell density. Overall, C albicans 
had shown greater biofilm formation ability in both experimental approaches, which is 
in line with other studies [17]. Furthermore, to investigate whether the inhibitory 
mechanism of imidazole derivatives affected the different cellular morphologies of C. 
albicans and C. krusei, microscopic analysis was performed by SEM. Regarding C. 
albicans, a predominantly blastospore morphology was observed on drug-free samples. 
Such behaviour may be related to the hydrophilic nature of nanoHA [21]. As pointed 
out by other authors, the adherence of the yeast form is increased by hydrophilic 
coatings [38]. Moreover, it has been reported that Candida spp adhered more rapidly to 
hydrophobic surfaces due to its hydrophobic nature, which means that in the presence of 
a hydrophilic surface repulsive interactions take place between both surfaces and, 
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consequently, it could dictate the lesser biofilm network formed on nanoHA surface 
after 24 hours incubation [4, 39]. In this context, Frade et al [40] also demonstrated that 
C. albicans biofilms showed less metabolic activity on hydrophilic surfaces. 
Concerning C. krusei, the greater cell surface hydrophobicity, as determined by 
Samaranayake et al [39], might lead to a lower ability to adhere and proliferate on 
nanoHA, compared to C. albicans. After exposure to the imidazole derivatives, different 
effects were observed according the Candida species. For C. albicans a dimorphic 
transition, from yeast to filamentous growth forms, was observed. The cellular 
structures remained with a full shape and smooth surface, similar to those observed by 
Nieminen et al [41] in the control group. These morphological switches, as well as the 
overall heterogeneous morphology are common features of C. albicans biofilm. 
Filamentous growth, although not strictly essential for biofilm formation per se, 
strengthens the entire structure and provides protection and adhesion sites for the 
budding yeast cells, and it occurs in response to distinct environmental stimuli [16, 42, 
43]. Although the substrate surface plays a role in C. albicans attachment, the mixture 
of morphological forms after exposure to the compounds strengthens the hypothesis that 
the chemical nature of imidazol derivatives, in particular 2h compound, could induce a 
phenotypic response in this species, which is a sign of cell virulence, once both hyphae 
and pseudohyphae might promote tissue invasion during the early stages of infection 
[43]. On the other hand, C. krusei exhibited its ‘large American rice grain’ form devoid 
of hyphal elements as also observed by Parahitiyawa et al [11]. The exposure to the 
imidazole derivatives seems to have induced the formation of microcolonies on nanoHA 
surface. The majority of cell surfaces were smooth and free of wrinkles, albeit some of 
them presented disc-like depressions, in accordance to that recently reported by Ma et al 
[44]. Sample preparation for SEM usually requires an approach that subjects samples to 
mechanical and physical stress and can alter normal biofilm morphology, however such 
artefacts might be dismissed in the present study since only localized cell damage were 
seen, most likely induced by the imidazol derivatives. As suggested by Ma et al [44], 
and in line with our results, such morphological changes may indicate that the 
antifungal effect was the result of a loss of integrity of the cell surface and changes in 
cell membrane permeability. The morphological alterations associated to each specific 
Candida species underline that different effects are occurring. This is one of the reasons 
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why it was considered relevant to introduce in this study the use of two different 
Candida species instead of only one, often C. albicans, because, as observed, major 
differences between species with respect to susceptibility profiles and the ability to 
adhere to biomaterial surfaces were identified, even so this study would benefit from 
confirmation with further Candida species and clinical isolates due to inter-strain 
variations. 
A especially important characteristic of all biofilms is the presence and 
composition of the extracellular matrix that serves as a diffusion barrier to antifungal 
agents [4]. However, in the present study both Candida species were apparently devoid 
of extracellular polymeric material covering the fungal microcolonies. Similar 
evidences were reported by Samaranayake et al [45]. The matrix is usually difficult to 
preserve for SEM observation. However, the presence of Candida matrix depends not 
only on preparative techniques but also on the incubation conditions during biofilm 
development [2]. The absence of matrix might partly explain the high sensitivity of 
Candida spp to the imidazole derivatives. Regarding the cytocompatibility assays, 
parallel results were found between the same compounds, for both approaches. Which 
means that independently from time of compounds administration, a time-dependent 
cytotoxicity is noticed. By combining the results of cytocompatibility and antifungal 
activity, it may be observed that 2h compound showed the less appealing results once 
the majority of C. albicans cells showed dimorphic transition and a significant reduction 
in the number of remaining viable cells was only observed for concentrations as high as 
the MIC (50 µg/mL) for the pre-formed biofilm experiment with the highest inoculum 
concentration tested (Fig. 3), for which high cytotoxicity was observed (Figs. 6 and 7). 
On the contrary, 2l proved to be the most effective compound for both C. albicans and 
C. krusei for the lowest concentrations tested 12.5 and 1.6 µg/mL, respectively, with no 
cytotoxic effect against MG-63 cell line. 
 
5. CONCLUSION 
The three tested 5-aminoimidazole-4-carboxamidrazones derivatives, in particular the 2l 
compound, have shown to present promising therapeutic potential to hamper biofilm-
based device-related infections caused by pathogenic fungi since they display powerful 
in vitro activity against C. albicans and C. krusei biofilm formation and pre-formed 
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biofilms, that have shown to be otherwise refractory to treatment with the most 
commonly used antifungal agents. Additionally, the antifungal resistance of biofilm-
grown cells increased in conjunction with biofilm formation therefore, a winning 
strategy shall need to address the first moments of yeast adhesion, as preventive 
measure. Furthermore, 2l compound exhibited the best cell viability values. Summing-
up all the obtained results, the 2l compound ought to be further investigated as a 
potentially reliable antifungal agent for local therapy. 
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GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
In 1973, Andriole was among the first researchers to realize that foreign bodies 
could potentiate the development of osteomyelitis [1]. Since then, a long way has been 
covered both to understand the biological principles behind such clinical events and to 
design strategies to avoid them. At present, there is not a single strategy that could 
totally eliminate the incidence of infections associated to biomaterials. Microbial 
adhesion and subsequent biofilm formation are major threats to human health as they 
are inherently resistant to clearance by both the host immune system and antibiotics [2, 
3]. Engineered implants to prevent infection are therefore a bubbling field with a wide 
range of strategies being explored to impair microbial adhesion. In particular, tissue 
engineered scaffolds for bone applications provide a convenient framework for tissue 
repair, as well as a substrate for the inclusion of antimicrobial agents, to prevent and 
treat infections after surgical intervention. Introducing anti-infection properties into 
regenerative medicine therapies could improve clinical outcomes and reduce the 
morbidity and mortality associated with biomaterial implant-related infections. 
Synthetic nanoHA is a beneficial material for medical applications due to good 
physicochemical similarity with bone [4], which opens up opportunities for applications 
throughout the body, for instance as a local delivery system of antibiotics. Although this 
type of approach has generally shown favourable results regarding their efficacy, there 
are a number of challenges which may slow down its clinical application, above all the 
emergence of new antibiotic resistant clinical strains [5, 6]. Therefore, finding 
treatments that can alter the phenotype of the bacteria without inducing and selecting for 
genetic modifications that could lead to resistance is a key factor in winning the battle 
against these pathogens. One strategy explored in this work was the use of ZnO due to 
its well-known antimicrobial activity [7]. In comparison with organic agents, the use of 
inorganic compounds, such as ZnO, for the production of nanoHA-ZnO composites has 
several practical advantages. They are more robust, resist to harsh process conditions 
and are capable of being synthesized in large quantities with a desired composition, 
reproducible size and structure. Their higher durability and stability promote a long-
term shelf-life, which is a key condition for the use of a biomaterial in clinical settings. 
Furthermore, this experimental strategy does not lead to emergence of resistant bacteria; 
it may mitigate concerns about multi-drug resistant super-bugs commonly seen in 
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conjunction with approaches based on conventional antibiotics. A step ahead, three-
dimensional and interconnected nanostructured porous granules of HA incorporated 
with small amounts of ZnO nanoparticles were produced and the resulting biomaterials 
supported tissue recovery, with the presence of new blood vessels and tissue 
regeneration in vivo and protected the biomaterial surfaces from biofilm formation not 
only in vitro but also in vivo. Regarding the organic agents, not everything is weakness. 
For instance, propolis can be by itself a bioactive product or be a promising source of 
new bioactive compounds. Additionally, it poses low risk for the development of 
resistance and presents high bioavailability [8]. A last approach addressed in this work 
was the use of new imidazole-based components to act against Candida spp biofilm. 
The preliminary results obtained showed promising therapeutic potential of these 
components to be used either as preventive measure or treatment procedure in the case 
of biomaterial-related infections by fungi. 
Beside the aforementioned approaches, which were successfully tested, the 
development of surfaces with multiple functionalities is therefore a new challenge for 
biomaterials engineering. Such surfaces should combine the need for implants 
possessing anti-infective properties with much needed maintenance of peri-operative 
tissue homeostasis. Under these circumstances multifunctional surfaces may give host 
cells a leg up in winning the race for the surface [9], as opposed to often-reported mono-
functional surface chemistries and morphologies that either discourage microbial 
adhesion and biofilm growth or promote host tissue integration but cannot reach both 
simultaneously [10]. To achieve such goal, Muszanska et al [11] work describes the 
synthesis and characterization of a polymer-peptide conjugates to be used as infection-
resistant coating for biomaterial implants. Anti-adhesive polymer brushes composed of 
block copolymer Pluronic F-127 were functionalized with AMP, being able to kill 
bacteria on contact, and arginine-glycine-aspartate acid (RGD) peptides to promote the 
adhesion and spreading of host tissue cells. The novel bioactive surfaces showed good 
anti-adhesive and bactericidal properties against S. aureus, S. epidermidis and P. 
aeruginosa, without hampering tissue compatibility. Another example of such approach 
is the work developed by Pishbin and colleagues [12] which tested multi-functionalizing 
chitosan-based composite coatings involving addition of bioactive glass particles and 
gentamicin as a molecular antibacterial agent. The coatings showed to be bioactive and 
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the gentamicin release kinetics could inhibit bacterial growth for the first 2 days and 
could support cellular proliferation for up to 10 days. Several others approaches for 
multifunctional surfaces have been proposed and tested [13-16], with very promising 
results. Nonetheless, they need to fulfil some practical requirements namely: they 
should be easily applicable to the surface of a large number of (ingrowth and non-
ingrowth) implants, have a longer-term effectiveness, demonstrate no local and systemic 
toxicity and be cost-effective. 
In the near future, it might be possible to develop multifunctional, self-
responsive, and self-repairing biomaterials refereed as ‘smart coatings’. These coatings 
are designed to be sensitive to various external and internal stimuli, thereby enhancing 
the surface functionality of materials. It is anticipated that these coatings respond 
intelligently to signalling depending on how they are prepared. Accordingly, smart 
coatings should possess synergistic passive and active functionalities [17, 18]. The most 
sophisticated part of smart coatings is the development of nanocontainers with sensitive 
shells, high loading capacity, and good affinity for the coating matrix. The sensor unit is 
also a critical component of a smart micro-device that should be sensitive enough to 
detect even the earliest microbial-associated signals. For instance, nanocontainer shell 
entryway signals include pH, temperature, as well as mechanical, chemical, and 
electrical (electrochemical) changes in the peri-implant effective space. Stimulation 
should then lead to the opening of the nanocontainers and release of specific 
substance(s) [17, 19, 20]. For example, nanopatterned poly(N-isopropylacrylamide)/ 
quaternary ammonium salt hybrid surfaces are model systems that exhibit an ability to 
undergo non-covalent, dynamic, and reversible changes in structure that can be used to 
control the attachment, killing, and release of bacteria in response to changes in 
temperature [21]. Some of the challenges encountered during the development of these 
smart coatings have included: survivorship during the implant-coating manufacturing 
process, non-adverse reactions to the smart coatings themselves in vivo, mechanical 
resistance, and preservation of intended functionalities throughout the device’s expected 
and functional life time [17, 22]. 
The critical aspect for the effective translation of novel biomaterials from the 
laboratory to the clinic is the current commonly used pre-clinical validation methods, 
either in vitro or in vivo. There is no widely accepted methodology available that could 
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precisely and reproducibly demonstrate antimicrobial behaviour of the proposed anti-
infective approaches. Controllable, standardized methods, in particular to test biofilm-
growing bacteria, must be improved, to more accurately reflect the clinical situation, 
including the influence of physiologically relevant conditioning films, the use of 
relevant pathogenic species and the host response. Therefore, a more precise prediction 
of biomaterial clinical success could be expected. Examination of published studies on 
this topic suggests a striking discrepancy between proposed strategies of antibacterial 
surface treatment and ultimate completion of in vitro and in vivo experimentation. 
Barriers to translational medicine in this field are most likely related to economic, 
medico-legal, and biotechnological issues. Concerns about the long-term durability of 
such new implantable devices as compared to traditional implants are also realistic. 
Only by improving collaborative efforts between governments, regulatory agencies, 
industry leaders and health care players will patients benefit from these technologies 
[22, 23]. 
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